Trial Outcomes & Findings for A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (NCT NCT03602859)
NCT ID: NCT03602859
Last Updated: 2025-12-31
Results Overview
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
Recruitment status
ACTIVE_NOT_RECRUITING
Study phase
PHASE3
Target enrollment
1400 participants
Primary outcome timeframe
Up to approximately 316 weeks
Results posted on
2025-12-31
Participant Flow
The results presented are based on primary completion date. Safety data collection is still ongoing, and additional results will be provided within a year of study completion.
Participant milestones
| Measure |
All Enrolled Participants
Eligible participants with ovarian cancer received standard of care (SOC) chemotherapy as combination of 175 milligram (mg)/meter\^2(m\^2) Paclitaxel, area under the curve (AUC) of 5 to 6 mg/millilitre (mL)/minute Carboplatin and optional 7.5 mg/kilogram (kg) or 15 mg/kg Bevacizumab as intravenous (IV) infusion on Day 1 of Cycle 1 in Chemotherapy Run-In Period.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo (Pbo) on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles starting with Cycle 2, with optional Bevacizumab (Bev) as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib placebo Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|---|---|
|
Chemotherapy Run-In Period (Cycle 1)
STARTED
|
1400
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
COMPLETED
|
1321
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
NOT COMPLETED
|
79
|
0
|
0
|
0
|
|
Chemo Treatment Period (Cycle 2 to 6)
STARTED
|
0
|
159
|
417
|
745
|
|
Chemo Treatment Period (Cycle 2 to 6)
ITT Population
|
0
|
193
|
385
|
753
|
|
Chemo Treatment Period (Cycle 2 to 6)
COMPLETED
|
0
|
129
|
371
|
645
|
|
Chemo Treatment Period (Cycle 2 to 6)
NOT COMPLETED
|
0
|
30
|
46
|
100
|
|
Maintenance Period (Cycle 7 to 89)
STARTED
|
0
|
129
|
371
|
645
|
|
Maintenance Period (Cycle 7 to 89)
COMPLETED
|
0
|
5
|
41
|
77
|
|
Maintenance Period (Cycle 7 to 89)
NOT COMPLETED
|
0
|
124
|
330
|
568
|
Reasons for withdrawal
| Measure |
All Enrolled Participants
Eligible participants with ovarian cancer received standard of care (SOC) chemotherapy as combination of 175 milligram (mg)/meter\^2(m\^2) Paclitaxel, area under the curve (AUC) of 5 to 6 mg/millilitre (mL)/minute Carboplatin and optional 7.5 mg/kilogram (kg) or 15 mg/kg Bevacizumab as intravenous (IV) infusion on Day 1 of Cycle 1 in Chemotherapy Run-In Period.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo (Pbo) on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles starting with Cycle 2, with optional Bevacizumab (Bev) as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib placebo Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|---|---|
|
Chemotherapy Run-In Period (Cycle 1)
Adverse Event
|
10
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Disease Progression per Clinical Criteria by Investigator
|
2
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Risk to Patient
|
3
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Severe Noncompliance to Protocol
|
6
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Withdrawal by Subject
|
10
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Death
|
10
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Other
|
27
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Missing
|
1
|
0
|
0
|
0
|
|
Chemotherapy Run-In Period (Cycle 1)
Randomized but not treated
|
10
|
0
|
0
|
0
|
|
Chemo Treatment Period (Cycle 2 to 6)
Investigator decision
|
0
|
1
|
5
|
3
|
|
Chemo Treatment Period (Cycle 2 to 6)
Adverse Event
|
0
|
7
|
11
|
25
|
|
Chemo Treatment Period (Cycle 2 to 6)
Progression/clinical progression
|
0
|
7
|
14
|
15
|
|
Chemo Treatment Period (Cycle 2 to 6)
Risk to Patient
|
0
|
2
|
1
|
5
|
|
Chemo Treatment Period (Cycle 2 to 6)
Severe Noncompliance to Protocol
|
0
|
2
|
2
|
8
|
|
Chemo Treatment Period (Cycle 2 to 6)
Withdrawal by Subject
|
0
|
9
|
11
|
29
|
|
Chemo Treatment Period (Cycle 2 to 6)
Lost to Follow-up
|
0
|
0
|
0
|
1
|
|
Chemo Treatment Period (Cycle 2 to 6)
Death
|
0
|
1
|
1
|
5
|
|
Chemo Treatment Period (Cycle 2 to 6)
Other
|
0
|
1
|
1
|
9
|
|
Maintenance Period (Cycle 7 to 89)
Ongoing
|
0
|
3
|
23
|
42
|
|
Maintenance Period (Cycle 7 to 89)
Adverse Event
|
0
|
6
|
24
|
91
|
|
Maintenance Period (Cycle 7 to 89)
Thrombocytopenia Platelet Count not Returned to >=100000 cells/uL w/in
|
0
|
0
|
1
|
2
|
|
Maintenance Period (Cycle 7 to 89)
Progression/clinical progression
|
0
|
83
|
251
|
356
|
|
Maintenance Period (Cycle 7 to 89)
Risk to Patient
|
0
|
2
|
1
|
2
|
|
Maintenance Period (Cycle 7 to 89)
Severe Noncompliance to Protocol
|
0
|
3
|
3
|
5
|
|
Maintenance Period (Cycle 7 to 89)
Withdrawal by Subject
|
0
|
7
|
22
|
48
|
|
Maintenance Period (Cycle 7 to 89)
Lost to Follow-up
|
0
|
0
|
2
|
2
|
|
Maintenance Period (Cycle 7 to 89)
Death
|
0
|
0
|
1
|
7
|
|
Maintenance Period (Cycle 7 to 89)
Unblinded due to being randomized to Arm 1
|
0
|
18
|
0
|
0
|
|
Maintenance Period (Cycle 7 to 89)
Investigator decision
|
0
|
0
|
0
|
1
|
|
Maintenance Period (Cycle 7 to 89)
Other
|
0
|
2
|
2
|
12
|
Baseline Characteristics
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Baseline characteristics by cohort
| Measure |
All Enrolled Participants
n=1400 Participants
Eligible participants with ovarian cancer received standard of care (SOC) chemotherapy as combination of 175 milligram (mg)/meter\^2(m\^2) Paclitaxel, area under the curve (AUC) of 5 to 6 mg/millilitre (mL)/minute Carboplatin and optional 7.5 mg/kilogram (kg) or 15 mg/kg Bevacizumab as intravenous (IV) infusion on Day 1 of Cycle 1 in Chemotherapy Run-In Period.
|
|---|---|
|
Age, Continuous
|
62.0 YEARS
STANDARD_DEVIATION 10.81 • n=1000 Participants
|
|
Sex: Female, Male
Female
|
1400 Participants
n=1000 Participants
|
|
Sex: Female, Male
Male
|
0 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
White
|
1245 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
Black or African American
|
30 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
Asian
|
29 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
American Indian or Alaska Native
|
8 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
Unknown
|
80 Participants
n=1000 Participants
|
|
Race/Ethnicity, Customized
Not Reported
|
8 Participants
n=1000 Participants
|
PRIMARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first by the Investigator assessment according to Response Evaluation Criteria in Solid Tumors Criteria (RECIST) version 1.1. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Progression Free Survival (PFS)
|
19.19 Months
Interval 16.59 to 20.99
|
20.63 Months
Interval 19.22 to 22.77
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Overall Survival (OS) is defined as the time from the date of randomization to the date of death by any cause.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Overall Survival (OS)
|
45.37 Months
Interval 40.28 to 52.21
|
44.39 Months
Interval 41.17 to 47.54
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Progression Free Survival (PFS) is defined as the time from the date of randomization to the date of first documented progressive disease (PD) or death due to any cause, whichever occurs first determined by the BICR according to RECIST version 1.1. Progressive Disease was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5mm.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
PFS Determined by Blinded Independent Central Review (BICR) Per RECIST v1.1 Criteria
|
23.56 Months
Interval 20.14 to 27.4
|
25.89 Months
Interval 23.36 to 32.49
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Time to First Subsequent Therapy (TFST) is defined as the time from randomization until the start date of the first subsequent anticancer therapy or death by any cause, whichever occurs first. First subsequent anticancer therapy is defined as the earliest anticancer therapy on the follow-up anticancer therapy form.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Time to First Subsequent Therapy (TFST)
|
20.93 Months
Interval 17.58 to 22.67
|
20.86 Months
Interval 19.15 to 23.92
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Time to Second Subsequent Therapy (TSST) is defined as the time from the date of randomization to the start date of the second subsequent anticancer therapy or death of any cause, whichever occurs first. Second subsequent anticancer therapy is defined as an anticancer therapy with a start date after the first subsequent anticancer therapy and a recorded PD on first subsequent anticancer therapy, as captured on the follow-up anticancer therapy eCRF form.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Time to Second Subsequent Therapy (TSST)
|
33.97 Months
Interval 30.06 to 37.49
|
35.32 Months
Interval 32.46 to 38.31
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
PFS2 is defined as the time from the date of randomization to the date of first Progressive Disease per Investigator's assessment after initiation of subsequent anticancer therapy or death due to any cause, whichever occurs first. Progressive Disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 millimeter (mm).
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Time to Second Progression (PFS2)
|
31.84 Months
Interval 28.65 to 35.09
|
32.69 Months
Interval 30.42 to 35.38
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Objective Response Rate (ORR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR) or partial response (PR) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Objective Response Rate (ORR)
|
88 Percentage of participants
Interval 83.7 to 91.6
|
88.4 Percentage of participants
Interval 85.5 to 90.9
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
DOR is defined as the time from the first documented response (complete response (CR) OR partial response (PR) ) to the first documented disease progression per Investigator assessed RECIST v1.1 or death by any cause in participants with measurable disease at baseline who responded to treatment. PR was defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PD was defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g. percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=250 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=496 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Duration of Response (DOR)
|
16.07 Months
Interval 13.86 to 18.4
|
18.27 Months
Interval 16.36 to 20.53
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: The Intent-to-Treat (ITT) population included all randomized participants. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
Disease Control Rate (DCR) is defined as the percentage of participants with measurable disease at baseline achieving a best overall response (BOR) of complete response (CR), partial response (PR) or stable disease (SD) by Investigator assessment per RECIST v1.1 criteria for participants with measurable disease at baseline. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. CR is defined as the disappearance of all target lesions. SD defined as any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (\<)10 mm.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=385 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=753 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Disease Control Rate (DCR)
|
93.7 Percentage of participants
Interval 90.2 to 96.2
|
93.6 Percentage of participants
Interval 91.2 to 95.5
|
SECONDARY outcome
Timeframe: Up to approximately 316 weeksPopulation: Anti-drug antibody (ADA) population included all participants from Arm 3 only who received at least one dose of dostarlimab and who had at least 1 ADA sample with an assay result.
Serum samples were collected for the analysis of Anti-drug antibody (ADAs) of dostarlimab.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=745 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Number of Participants With Treatment Emergent Positive Antidrug Antibodies (ADAs) of Dostarlimab
|
17 Participants
|
—
|
SECONDARY outcome
Timeframe: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)Population: ITT Population.Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
EQ-5D-5L is a standardized, participant-rated health outcomes questionnaire covering five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. For each of dimensions, participant self-assigned score: 1 (no problems); 2 (slight problems); 3 (moderate problems); 4 (severe problems); 5 (extreme problems). VAS is collected separately and recorded from 0 (Worst imaginable health state) to 100 (Best imaginable health state). HUI values summarize how good or bad each health state is on a scale of 1 (full health) to 0 (worse health/dead). High HUI value indicates a good HRQoL. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment (EOT).
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=330 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=655 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 17 Maintenance
|
14.8 Scores on a scale
Standard Deviation 26.29
|
11.5 Scores on a scale
Standard Deviation 19.81
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 41 Maintenance
|
9.8 Scores on a scale
Standard Deviation 22.91
|
10.1 Scores on a scale
Standard Deviation 18.96
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 89 Maintenance
|
—
|
-5.0 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 33 months
|
4.6 Scores on a scale
Standard Deviation 21.75
|
9.2 Scores on a scale
Standard Deviation 17.02
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 45 months
|
5.5 Scores on a scale
Standard Deviation 19.23
|
-4.7 Scores on a scale
Standard Deviation 16.00
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 21 months
|
-0.0370 Scores on a scale
Standard Deviation 0.16768
|
-0.0457 Scores on a scale
Standard Deviation 0.26270
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 4 Chemotherapy
|
1.2 Scores on a scale
Standard Deviation 18.33
|
0.1 Scores on a scale
Standard Deviation 18.00
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 6 Chemotherapy
|
4.6 Scores on a scale
Standard Deviation 18.84
|
2.0 Scores on a scale
Standard Deviation 18.69
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 1 Maintenance
|
5.9 Scores on a scale
Standard Deviation 19.99
|
3.2 Scores on a scale
Standard Deviation 18.25
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 2 Maintenance
|
6.9 Scores on a scale
Standard Deviation 19.03
|
2.9 Scores on a scale
Standard Deviation 19.52
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 3 Maintenance
|
4.9 Scores on a scale
Standard Deviation 20.42
|
4.9 Scores on a scale
Standard Deviation 19.32
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 6 Maintenance
|
5.1 Scores on a scale
Standard Deviation 17.81
|
5.3 Scores on a scale
Standard Deviation 18.80
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 9 Maintenance
|
7.6 Scores on a scale
Standard Deviation 19.74
|
6.6 Scores on a scale
Standard Deviation 18.09
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 12 Maintenance
|
9.6 Scores on a scale
Standard Deviation 20.58
|
6.6 Scores on a scale
Standard Deviation 17.59
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 15 Maintenance
|
8.1 Scores on a scale
Standard Deviation 23.56
|
6.6 Scores on a scale
Standard Deviation 17.72
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 23 Maintenance
|
13.3 Scores on a scale
Standard Deviation 22.95
|
10.4 Scores on a scale
Standard Deviation 20.89
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 29 Maintenance
|
12.5 Scores on a scale
Standard Deviation 22.27
|
10.3 Scores on a scale
Standard Deviation 19.06
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 35 Maintenance
|
9.9 Scores on a scale
Standard Deviation 19.00
|
10.4 Scores on a scale
Standard Deviation 16.55
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 47 Maintenance
|
8.8 Scores on a scale
Standard Deviation 21.16
|
10.9 Scores on a scale
Standard Deviation 18.39
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 53 Maintenance
|
8.5 Scores on a scale
Standard Deviation 25.94
|
11.4 Scores on a scale
Standard Deviation 18.65
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 59 Maintenance
|
7.3 Scores on a scale
Standard Deviation 25.15
|
10.7 Scores on a scale
Standard Deviation 18.14
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 65 Maintenance
|
2.5 Scores on a scale
Standard Deviation 11.10
|
14.9 Scores on a scale
Standard Deviation 19.55
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 71 Maintenance
|
5.9 Scores on a scale
Standard Deviation 10.78
|
13.0 Scores on a scale
Standard Deviation 17.09
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 77 Maintenance
|
9.3 Scores on a scale
Standard Deviation 9.84
|
15.9 Scores on a scale
Standard Deviation 18.65
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Cycle 83 Maintenance
|
9.7 Scores on a scale
Standard Deviation 6.35
|
19.3 Scores on a scale
Standard Deviation 21.45
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, End of Treatment
|
0.7 Scores on a scale
Standard Deviation 21.93
|
-0.1 Scores on a scale
Standard Deviation 22.51
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Safety Follow-up
|
3.5 Scores on a scale
Standard Deviation 21.89
|
-0.1 Scores on a scale
Standard Deviation 21.45
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, Long term Follow-up (LTFU) EOT + 3 months
|
3.0 Scores on a scale
Standard Deviation 21.47
|
2.7 Scores on a scale
Standard Deviation 20.06
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 9 months
|
1.1 Scores on a scale
Standard Deviation 18.14
|
2.4 Scores on a scale
Standard Deviation 21.53
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 15 months
|
2.3 Scores on a scale
Standard Deviation 21.57
|
4.3 Scores on a scale
Standard Deviation 19.29
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 21 months
|
1.8 Scores on a scale
Standard Deviation 19.39
|
1.8 Scores on a scale
Standard Deviation 24.79
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 27 months
|
5.5 Scores on a scale
Standard Deviation 15.87
|
5.0 Scores on a scale
Standard Deviation 21.42
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 39 months
|
5.9 Scores on a scale
Standard Deviation 22.38
|
-1.9 Scores on a scale
Standard Deviation 13.89
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 51 months
|
0.0 Scores on a scale
Standard Deviation 0.0
|
3.6 Scores on a scale
Standard Deviation 11.50
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 57 months
|
2.5 Scores on a scale
Standard Deviation 3.54
|
-12.0 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
EQ-VAS, LTFU-EOT + 63 months
|
0.0 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
—
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 4 Chemotherapy
|
-0.0033 Scores on a scale
Standard Deviation 0.16847
|
-0.0035 Scores on a scale
Standard Deviation 0.19281
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 6 Chemotherapy
|
-0.0049 Scores on a scale
Standard Deviation 0.18207
|
-0.0065 Scores on a scale
Standard Deviation 0.19647
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 1 Maintenance
|
0.0034 Scores on a scale
Standard Deviation 0.19324
|
-0.0043 Scores on a scale
Standard Deviation 0.20270
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 2 Maintenance
|
0.0118 Scores on a scale
Standard Deviation 0.18781
|
0.0036 Scores on a scale
Standard Deviation 0.20052
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 3 Maintenance
|
-0.0015 Scores on a scale
Standard Deviation 0.21441
|
-0.0073 Scores on a scale
Standard Deviation 0.21785
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 6 Maintenance
|
0.0184 Scores on a scale
Standard Deviation 0.21704
|
0.0029 Scores on a scale
Standard Deviation 0.19389
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 9 Maintenance
|
0.0281 Scores on a scale
Standard Deviation 0.19001
|
0.0181 Scores on a scale
Standard Deviation 0.20597
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 12 Maintenance
|
0.0326 Scores on a scale
Standard Deviation 0.21333
|
0.0177 Scores on a scale
Standard Deviation 0.19577
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 15 Maintenance
|
0.0379 Scores on a scale
Standard Deviation 0.21060
|
0.0136 Scores on a scale
Standard Deviation 0.18809
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 17 Maintenance
|
0.0777 Scores on a scale
Standard Deviation 0.23603
|
0.0545 Scores on a scale
Standard Deviation 0.19913
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 23 Maintenance
|
0.0353 Scores on a scale
Standard Deviation 0.16562
|
0.0012 Scores on a scale
Standard Deviation 0.22021
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 29 Maintenance
|
0.0610 Scores on a scale
Standard Deviation 0.23268
|
0.0058 Scores on a scale
Standard Deviation 0.18551
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 35 Maintenance
|
0.0295 Scores on a scale
Standard Deviation 0.20956
|
0.0175 Scores on a scale
Standard Deviation 0.19186
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 41 Maintenance
|
0.0247 Scores on a scale
Standard Deviation 0.23996
|
0.0084 Scores on a scale
Standard Deviation 0.22003
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 47 Maintenance
|
0.0251 Scores on a scale
Standard Deviation 0.20478
|
0.0263 Scores on a scale
Standard Deviation 0.19109
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 53 Maintenance
|
0.0285 Scores on a scale
Standard Deviation 0.17721
|
-0.0270 Scores on a scale
Standard Deviation 0.20412
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 59 Maintenance
|
0.0156 Scores on a scale
Standard Deviation 0.11589
|
-0.0210 Scores on a scale
Standard Deviation 0.19579
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 65 Maintenance
|
0.0358 Scores on a scale
Standard Deviation 0.10770
|
-0.0302 Scores on a scale
Standard Deviation 0.20843
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 71 Maintenance
|
0.0604 Scores on a scale
Standard Deviation 0.08941
|
0.0165 Scores on a scale
Standard Deviation 0.11503
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 77 Maintenance
|
0.0783 Scores on a scale
Standard Deviation 0.06087
|
0.0193 Scores on a scale
Standard Deviation 0.20537
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 83 Maintenance
|
0.0200 Scores on a scale
Standard Deviation 0.09952
|
0.0720 Scores on a scale
Standard Deviation 0.08398
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Cycle 89 Maintenance
|
—
|
0.0640 Scores on a scale
Standard Deviation 0.09051
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, End of Treatment
|
-0.0251 Scores on a scale
Standard Deviation 0.22757
|
-0.0310 Scores on a scale
Standard Deviation 0.24320
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, Safety Follow-up
|
-0.0326 Scores on a scale
Standard Deviation 0.22131
|
-0.0460 Scores on a scale
Standard Deviation 0.23927
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU- EOT + 3 months
|
-0.0439 Scores on a scale
Standard Deviation 0.22896
|
-0.0222 Scores on a scale
Standard Deviation 0.22768
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 9 months
|
-0.0723 Scores on a scale
Standard Deviation 0.20713
|
-0.0400 Scores on a scale
Standard Deviation 0.23756
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 15 months
|
-0.0323 Scores on a scale
Standard Deviation 0.20492
|
-0.0386 Scores on a scale
Standard Deviation 0.22117
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 27 months
|
-0.0407 Scores on a scale
Standard Deviation 0.17664
|
-0.0635 Scores on a scale
Standard Deviation 0.23835
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 33 months
|
-0.0547 Scores on a scale
Standard Deviation 0.15663
|
-0.0114 Scores on a scale
Standard Deviation 0.23974
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 39 months
|
-0.0374 Scores on a scale
Standard Deviation 0.11831
|
-0.0993 Scores on a scale
Standard Deviation 0.24071
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 45 months
|
-0.0568 Scores on a scale
Standard Deviation 0.14026
|
-0.0648 Scores on a scale
Standard Deviation 0.23505
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 51 months
|
0.0000 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
0.0028 Scores on a scale
Standard Deviation 0.18532
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 57 months
|
-0.0780 Scores on a scale
Standard Deviation 0.11031
|
0.0000 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
|
Change From Baseline (CFB) for the Visual Analogue Score (VAS) and Health Utility Index (HUI) of European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L) Questionnaire
HUI, LTFU-EOT + 63 months
|
0.0000 Scores on a scale
Standard Deviation NA
Standard deviation is not applicable as only a single participant was analyzed.
|
—
|
SECONDARY outcome
Timeframe: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)Population: ITT Population.Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
The EORTC QLQ-C30 includes 30-items with single and multi-item scales. These included five functional scales (physical functioning \[PF\], role functioning \[RF\], cognitive functioning \[CF\], emotional functioning \[EF\] and social functioning \[SF\]), three symptom scales (fatigue, pain and nausea/vomiting \[N/V\]), a global health status (GHS)/ Quality-of-Life (QoL) scale, and six single items (constipation, diarrhoea, insomnia, dyspnoea, appetite loss \[AL\] and financial difficulties \[FD\]). Response options are 1 to 4. Scores were averaged and transformed to 0 to 100, a high score for functional scales/ GHS/QoL represent better functioning ability or health-related quality-of-life (HRQoL), whereas a high score for symptom scales/ single items represent significant symptomatology.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=336 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=666 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 4 Chemotherapy · Stable
|
196 Participants
|
373 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Chemotherapy · Stable
|
135 Participants
|
301 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Chemotherapy · Worsened
|
34 Participants
|
78 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 1 Maintenance · Worsened
|
50 Participants
|
135 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 1 Maintenance · Stable
|
178 Participants
|
317 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 2 Maintenance · Worsened
|
58 Participants
|
139 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 2 Maintenance · Improved
|
60 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 2 Maintenance · Stable
|
68 Participants
|
138 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 2 Maintenance · Improved
|
95 Participants
|
159 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 2 Maintenance · Worsened
|
34 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 2 Maintenance · Stable
|
155 Participants
|
277 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 2 Maintenance · Worsened
|
29 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 2 Maintenance · Improved
|
71 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 3 Maintenance · Stable
|
110 Participants
|
199 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 3 Maintenance · Worsened
|
49 Participants
|
130 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 3 Maintenance · Worsened
|
83 Participants
|
183 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 3 Maintenance · Stable
|
101 Participants
|
185 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 3 Maintenance · Stable
|
51 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 3 Maintenance · Worsened
|
58 Participants
|
133 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 3 Maintenance · Stable
|
171 Participants
|
327 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Maintenance · Worsened
|
52 Participants
|
100 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Maintenance · Improved
|
52 Participants
|
78 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Maintenance · Improved
|
38 Participants
|
75 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Maintenance · Improved
|
67 Participants
|
142 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Maintenance · Improved
|
93 Participants
|
167 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Maintenance · Improved
|
33 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Maintenance · Improved
|
59 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Maintenance · Improved
|
61 Participants
|
108 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 9 Maintenance · Stable
|
88 Participants
|
168 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 9 Maintenance · Stable
|
47 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 9 Maintenance · Improved
|
91 Participants
|
164 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 9 Maintenance · Worsened
|
35 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 9 Maintenance · Improved
|
41 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 53 Maintenance · Worsened
|
3 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 53 Maintenance · Improved
|
2 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 59 Maintenance · Stable
|
11 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 59 Maintenance · Improved
|
4 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 59 Maintenance · Stable
|
10 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 59 Maintenance · Improved
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 59 Maintenance · Stable
|
11 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 65 Maintenance · Worsened
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 77 Maintenance · Worsened
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 77 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 83 Maintenance · Stable
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 83 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 83 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 83 Maintenance · Stable
|
3 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 83 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 83 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 83 Maintenance · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 83 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 83 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 83 Maintenance · Improved
|
3 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 83 Maintenance · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 83 Maintenance · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 83 Maintenance · Improved
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, End of treatment (EOT) · Improved
|
53 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, EOT · Improved
|
59 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, EOT · Improved
|
62 Participants
|
125 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, EOT · Worsened
|
67 Participants
|
133 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, EOT · Stable
|
92 Participants
|
161 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, EOT · Improved
|
25 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 9 months) · Worsened
|
34 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 15 Maintenance · Stable
|
95 Participants
|
172 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 9 Maintenance · Improved
|
55 Participants
|
113 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 15 Maintenance · Improved
|
29 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 15 Maintenance · Worsened
|
37 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 15 Maintenance · Stable
|
73 Participants
|
128 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 9 Maintenance · Worsened
|
62 Participants
|
89 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 17 Maintenance · Worsened
|
8 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 9 Maintenance · Stable
|
83 Participants
|
189 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 9 Maintenance · Improved
|
44 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 9 Maintenance · Worsened
|
15 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 9 Maintenance · Stable
|
138 Participants
|
264 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 9 Maintenance · Improved
|
36 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 9 Maintenance · Worsened
|
18 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 9 Maintenance · Stable
|
145 Participants
|
276 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 9 Maintenance · Improved
|
27 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 12 Maintenance · Worsened
|
23 Participants
|
64 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 12 Maintenance · Stable
|
69 Participants
|
141 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 12 Maintenance · Improved
|
70 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 12 Maintenance · Worsened
|
22 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 12 Maintenance · Stable
|
82 Participants
|
167 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 12 Maintenance · Improved
|
57 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 12 Maintenance · Worsened
|
29 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 12 Maintenance · Stable
|
68 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 12 Maintenance · Improved
|
64 Participants
|
129 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 12 Maintenance · Worsened
|
31 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 12 Maintenance · Stable
|
82 Participants
|
181 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 12 Maintenance · Improved
|
49 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 12 Maintenance · Worsened
|
50 Participants
|
106 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 12 Maintenance · Stable
|
86 Participants
|
154 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 12 Maintenance · Improved
|
26 Participants
|
55 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 12 Maintenance · Worsened
|
27 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 12 Maintenance · Stable
|
69 Participants
|
123 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 12 Maintenance · Improved
|
66 Participants
|
117 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 12 Maintenance · Worsened
|
39 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 12 Maintenance · Stable
|
42 Participants
|
88 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 12 Maintenance · Improved
|
80 Participants
|
140 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 12 Maintenance · Worsened
|
21 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 12 Maintenance · Stable
|
105 Participants
|
190 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 12 Maintenance · Improved
|
35 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 12 Maintenance · Worsened
|
33 Participants
|
100 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 12 Maintenance · Stable
|
71 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 12 Maintenance · Improved
|
58 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 12 Maintenance · Worsened
|
27 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 12 Maintenance · Stable
|
107 Participants
|
197 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 12 Maintenance · Improved
|
26 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 12 Maintenance · Worsened
|
28 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 12 Maintenance · Stable
|
80 Participants
|
161 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 12 Maintenance · Improved
|
53 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 12 Maintenance · Worsened
|
12 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 12 Maintenance · Stable
|
99 Participants
|
173 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 12 Maintenance · Improved
|
50 Participants
|
92 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 12 Maintenance · Worsened
|
38 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 12 Maintenance · Stable
|
79 Participants
|
150 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 12 Maintenance · Improved
|
44 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 12 Maintenance · Worsened
|
12 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 12 Maintenance · Stable
|
119 Participants
|
221 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 12 Maintenance · Improved
|
31 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 12 Maintenance · Worsened
|
17 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 12 Maintenance · Stable
|
126 Participants
|
222 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 12 Maintenance · Improved
|
19 Participants
|
50 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 15 Maintenance · Worsened
|
26 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 15 Maintenance · Stable
|
67 Participants
|
142 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 15 Maintenance · Improved
|
60 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 15 Maintenance · Worsened
|
24 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 15 Maintenance · Stable
|
67 Participants
|
137 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 15 Maintenance · Improved
|
60 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 15 Maintenance · Worsened
|
25 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 15 Maintenance · Stable
|
60 Participants
|
108 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 15 Maintenance · Improved
|
68 Participants
|
118 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 15 Maintenance · Worsened
|
37 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 15 Maintenance · Stable
|
78 Participants
|
160 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 15 Maintenance · Improved
|
37 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 15 Maintenance · Worsened
|
54 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 15 Maintenance · Stable
|
78 Participants
|
120 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 15 Maintenance · Improved
|
21 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 15 Maintenance · Worsened
|
27 Participants
|
61 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 15 Maintenance · Stable
|
70 Participants
|
121 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 15 Maintenance · Improved
|
56 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 15 Maintenance · Worsened
|
38 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 15 Maintenance · Stable
|
40 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 15 Maintenance · Improved
|
75 Participants
|
132 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 15 Maintenance · Worsened
|
29 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 15 Maintenance · Stable
|
92 Participants
|
179 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 15 Maintenance · Improved
|
32 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 15 Maintenance · Worsened
|
38 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 15 Maintenance · Stable
|
58 Participants
|
102 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 4 Chemotherapy · Worsened
|
70 Participants
|
148 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 4 Chemotherapy · Stable
|
142 Participants
|
283 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 4 Chemotherapy · Improved
|
71 Participants
|
116 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 4 Chemotherapy · Worsened
|
77 Participants
|
150 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 4 Chemotherapy · Stable
|
146 Participants
|
290 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 4 Chemotherapy · Improved
|
60 Participants
|
108 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 4 Chemotherapy · Worsened
|
95 Participants
|
183 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 4 Chemotherapy · Stable
|
104 Participants
|
207 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 4 Chemotherapy · Improved
|
84 Participants
|
157 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 4 Chemotherapy · Worsened
|
46 Participants
|
128 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 4 Chemotherapy · Stable
|
179 Participants
|
317 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 4 Chemotherapy · Improved
|
58 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 4 Chemotherapy · Worsened
|
93 Participants
|
174 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 4 Chemotherapy · Stable
|
149 Participants
|
272 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 4 Chemotherapy · Improved
|
41 Participants
|
102 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 4 Chemotherapy · Worsened
|
95 Participants
|
201 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 4 Chemotherapy · Stable
|
120 Participants
|
220 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 4 Chemotherapy · Improved
|
67 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 4 Chemotherapy · Worsened
|
121 Participants
|
223 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 4 Chemotherapy · Stable
|
79 Participants
|
155 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 4 Chemotherapy · Improved
|
83 Participants
|
170 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 4 Chemotherapy · Worsened
|
47 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 4 Chemotherapy · Stable
|
191 Participants
|
363 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 4 Chemotherapy · Improved
|
45 Participants
|
94 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 4 Chemotherapy · Worsened
|
88 Participants
|
170 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 4 Chemotherapy · Stable
|
107 Participants
|
224 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 4 Chemotherapy · Improved
|
88 Participants
|
154 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 4 Chemotherapy · Worsened
|
59 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 4 Chemotherapy · Stable
|
179 Participants
|
346 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 4 Chemotherapy · Improved
|
45 Participants
|
99 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 4 Chemotherapy · Worsened
|
58 Participants
|
96 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 4 Chemotherapy · Stable
|
147 Participants
|
319 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 4 Chemotherapy · Improved
|
78 Participants
|
133 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 4 Chemotherapy · Worsened
|
53 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 4 Chemotherapy · Stable
|
163 Participants
|
322 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 4 Chemotherapy · Improved
|
67 Participants
|
115 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 4 Chemotherapy · Worsened
|
67 Participants
|
104 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 4 Chemotherapy · Stable
|
153 Participants
|
299 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 4 Chemotherapy · Improved
|
63 Participants
|
145 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 4 Chemotherapy · Worsened
|
41 Participants
|
82 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 4 Chemotherapy · Improved
|
46 Participants
|
93 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 4 Chemotherapy · Worsened
|
28 Participants
|
98 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 4 Chemotherapy · Stable
|
214 Participants
|
380 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 4 Chemotherapy · Improved
|
41 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Chemotherapy · Worsened
|
66 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Chemotherapy · Stable
|
133 Participants
|
260 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Chemotherapy · Improved
|
74 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Chemotherapy · Worsened
|
80 Participants
|
163 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Chemotherapy · Stable
|
131 Participants
|
274 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Chemotherapy · Improved
|
62 Participants
|
117 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Chemotherapy · Worsened
|
78 Participants
|
195 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Chemotherapy · Stable
|
104 Participants
|
189 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Chemotherapy · Improved
|
91 Participants
|
169 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Chemotherapy · Worsened
|
48 Participants
|
123 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Chemotherapy · Stable
|
162 Participants
|
316 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Chemotherapy · Improved
|
63 Participants
|
114 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Chemotherapy · Worsened
|
92 Participants
|
199 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Chemotherapy · Stable
|
144 Participants
|
260 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Chemotherapy · Improved
|
37 Participants
|
94 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Chemotherapy · Worsened
|
79 Participants
|
185 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Chemotherapy · Stable
|
116 Participants
|
222 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Chemotherapy · Improved
|
78 Participants
|
146 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Chemotherapy · Worsened
|
110 Participants
|
221 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Chemotherapy · Stable
|
71 Participants
|
163 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Chemotherapy · Improved
|
92 Participants
|
170 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Chemotherapy · Worsened
|
43 Participants
|
116 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Chemotherapy · Stable
|
182 Participants
|
340 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Chemotherapy · Improved
|
48 Participants
|
98 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Chemotherapy · Worsened
|
76 Participants
|
150 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Chemotherapy · Stable
|
99 Participants
|
220 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Chemotherapy · Improved
|
98 Participants
|
184 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Chemotherapy · Worsened
|
56 Participants
|
150 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Chemotherapy · Stable
|
174 Participants
|
316 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Chemotherapy · Improved
|
43 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Chemotherapy · Worsened
|
54 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Chemotherapy · Improved
|
84 Participants
|
142 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Chemotherapy · Worsened
|
44 Participants
|
113 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Chemotherapy · Stable
|
162 Participants
|
288 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Chemotherapy · Improved
|
67 Participants
|
153 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Chemotherapy · Worsened
|
51 Participants
|
117 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Chemotherapy · Stable
|
148 Participants
|
300 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Chemotherapy · Improved
|
73 Participants
|
136 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Chemotherapy · Stable
|
193 Participants
|
388 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Chemotherapy · Improved
|
46 Participants
|
88 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Chemotherapy · Worsened
|
35 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Chemotherapy · Stable
|
203 Participants
|
395 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Chemotherapy · Improved
|
35 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 1 Maintenance · Stable
|
138 Participants
|
241 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 1 Maintenance · Improved
|
78 Participants
|
126 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 1 Maintenance · Worsened
|
62 Participants
|
130 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 1 Maintenance · Stable
|
127 Participants
|
255 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 1 Maintenance · Improved
|
76 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 1 Maintenance · Worsened
|
73 Participants
|
144 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 1 Maintenance · Stable
|
100 Participants
|
186 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 1 Maintenance · Improved
|
93 Participants
|
172 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 1 Maintenance · Worsened
|
55 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 1 Maintenance · Stable
|
150 Participants
|
283 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 1 Maintenance · Improved
|
61 Participants
|
94 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 1 Maintenance · Worsened
|
96 Participants
|
181 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 1 Maintenance · Stable
|
132 Participants
|
246 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 1 Maintenance · Improved
|
38 Participants
|
77 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 1 Maintenance · Worsened
|
83 Participants
|
154 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 1 Maintenance · Stable
|
109 Participants
|
224 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 1 Maintenance · Improved
|
74 Participants
|
126 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 1 Maintenance · Worsened
|
89 Participants
|
180 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 1 Maintenance · Stable
|
71 Participants
|
145 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 1 Maintenance · Improved
|
106 Participants
|
179 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 1 Maintenance · Worsened
|
35 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 1 Maintenance · Improved
|
53 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 1 Maintenance · Worsened
|
58 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 1 Maintenance · Stable
|
104 Participants
|
186 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 1 Maintenance · Improved
|
104 Participants
|
191 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 1 Maintenance · Worsened
|
64 Participants
|
109 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 1 Maintenance · Stable
|
159 Participants
|
297 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 1 Maintenance · Improved
|
43 Participants
|
95 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 1 Maintenance · Worsened
|
49 Participants
|
98 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 1 Maintenance · Stable
|
143 Participants
|
253 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 1 Maintenance · Improved
|
74 Participants
|
153 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 1 Maintenance · Worsened
|
40 Participants
|
86 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 1 Maintenance · Stable
|
154 Participants
|
285 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 1 Maintenance · Improved
|
72 Participants
|
132 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 1 Maintenance · Worsened
|
54 Participants
|
88 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 1 Maintenance · Stable
|
143 Participants
|
270 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 1 Maintenance · Improved
|
68 Participants
|
145 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 1 Maintenance · Worsened
|
28 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 1 Maintenance · Stable
|
189 Participants
|
338 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 1 Maintenance · Improved
|
49 Participants
|
76 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 1 Maintenance · Worsened
|
33 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 1 Maintenance · Stable
|
195 Participants
|
361 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 1 Maintenance · Improved
|
38 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 2 Maintenance · Worsened
|
47 Participants
|
118 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 2 Maintenance · Stable
|
110 Participants
|
211 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 2 Maintenance · Improved
|
74 Participants
|
117 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 2 Maintenance · Worsened
|
43 Participants
|
107 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 2 Maintenance · Stable
|
115 Participants
|
236 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 2 Maintenance · Improved
|
72 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 2 Maintenance · Stable
|
83 Participants
|
151 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 2 Maintenance · Improved
|
89 Participants
|
155 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 2 Maintenance · Worsened
|
37 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 2 Maintenance · Stable
|
134 Participants
|
253 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 2 Maintenance · Worsened
|
78 Participants
|
160 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 2 Maintenance · Stable
|
117 Participants
|
208 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 2 Maintenance · Improved
|
36 Participants
|
78 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 2 Maintenance · Worsened
|
63 Participants
|
137 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 2 Maintenance · Stable
|
91 Participants
|
177 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 2 Maintenance · Improved
|
77 Participants
|
132 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 2 Maintenance · Worsened
|
55 Participants
|
146 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 2 Maintenance · Improved
|
108 Participants
|
161 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 2 Maintenance · Worsened
|
42 Participants
|
94 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 2 Maintenance · Stable
|
144 Participants
|
266 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 2 Maintenance · Improved
|
45 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 2 Maintenance · Worsened
|
48 Participants
|
128 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 2 Maintenance · Stable
|
88 Participants
|
159 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 2 Maintenance · Improved
|
41 Participants
|
77 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 2 Maintenance · Worsened
|
41 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 2 Maintenance · Stable
|
115 Participants
|
220 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 2 Maintenance · Improved
|
75 Participants
|
135 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 2 Maintenance · Stable
|
134 Participants
|
250 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 2 Maintenance · Improved
|
67 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 2 Maintenance · Worsened
|
42 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 2 Maintenance · Stable
|
118 Participants
|
249 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 2 Maintenance · Worsened
|
22 Participants
|
52 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 2 Maintenance · Stable
|
160 Participants
|
315 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 2 Maintenance · Improved
|
49 Participants
|
79 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 2 Maintenance · Worsened
|
26 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 2 Maintenance · Stable
|
175 Participants
|
316 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 2 Maintenance · Improved
|
30 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 3 Maintenance · Worsened
|
56 Participants
|
146 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 3 Maintenance · Improved
|
76 Participants
|
112 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 3 Maintenance · Stable
|
113 Participants
|
216 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 3 Maintenance · Improved
|
79 Participants
|
109 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 3 Maintenance · Worsened
|
68 Participants
|
146 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 3 Maintenance · Stable
|
85 Participants
|
163 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 3 Maintenance · Improved
|
88 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 3 Maintenance · Worsened
|
60 Participants
|
122 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 3 Maintenance · Stable
|
126 Participants
|
255 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 3 Maintenance · Improved
|
56 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 3 Maintenance · Stable
|
120 Participants
|
193 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 3 Maintenance · Improved
|
39 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 3 Maintenance · Worsened
|
63 Participants
|
152 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 3 Maintenance · Improved
|
78 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 3 Maintenance · Worsened
|
84 Participants
|
182 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 3 Maintenance · Improved
|
106 Participants
|
156 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 3 Maintenance · Worsened
|
70 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 3 Maintenance · Stable
|
122 Participants
|
241 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 3 Maintenance · Improved
|
49 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 3 Maintenance · Stable
|
95 Participants
|
167 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 3 Maintenance · Improved
|
89 Participants
|
157 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 3 Maintenance · Worsened
|
65 Participants
|
121 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 3 Maintenance · Stable
|
136 Participants
|
258 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 3 Maintenance · Improved
|
39 Participants
|
77 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 3 Maintenance · Worsened
|
55 Participants
|
115 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 3 Maintenance · Stable
|
117 Participants
|
221 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 3 Maintenance · Improved
|
69 Participants
|
121 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 3 Maintenance · Worsened
|
45 Participants
|
124 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 3 Maintenance · Stable
|
129 Participants
|
229 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 3 Maintenance · Improved
|
66 Participants
|
104 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 3 Maintenance · Worsened
|
73 Participants
|
125 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 3 Maintenance · Stable
|
110 Participants
|
221 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 3 Maintenance · Improved
|
58 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 3 Maintenance · Worsened
|
15 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 3 Maintenance · Stable
|
177 Participants
|
329 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 9 Maintenance · Improved
|
77 Participants
|
126 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 3 Maintenance · Improved
|
50 Participants
|
90 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 3 Maintenance · Worsened
|
31 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 3 Maintenance · Improved
|
40 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Maintenance · Worsened
|
30 Participants
|
89 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Maintenance · Stable
|
101 Participants
|
192 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 6 Maintenance · Improved
|
70 Participants
|
129 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Maintenance · Worsened
|
39 Participants
|
86 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Maintenance · Stable
|
96 Participants
|
222 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 6 Maintenance · Improved
|
65 Participants
|
101 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Maintenance · Stable
|
75 Participants
|
171 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 6 Maintenance · Improved
|
74 Participants
|
139 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Maintenance · Worsened
|
36 Participants
|
86 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 6 Maintenance · Stable
|
113 Participants
|
246 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Maintenance · Worsened
|
68 Participants
|
134 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 6 Maintenance · Stable
|
95 Participants
|
201 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Maintenance · Worsened
|
43 Participants
|
106 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 6 Maintenance · Stable
|
91 Participants
|
162 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Maintenance · Worsened
|
49 Participants
|
132 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 6 Maintenance · Stable
|
59 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Maintenance · Worsened
|
36 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Maintenance · Stable
|
126 Participants
|
247 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 6 Maintenance · Improved
|
39 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Maintenance · Worsened
|
44 Participants
|
96 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Maintenance · Stable
|
85 Participants
|
161 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 6 Maintenance · Improved
|
72 Participants
|
153 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 15 Maintenance · Improved
|
57 Participants
|
114 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Maintenance · Worsened
|
43 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 6 Maintenance · Stable
|
125 Participants
|
240 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Maintenance · Worsened
|
43 Participants
|
88 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 6 Maintenance · Stable
|
99 Participants
|
211 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Maintenance · Worsened
|
29 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 6 Maintenance · Stable
|
111 Participants
|
232 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Maintenance · Worsened
|
62 Participants
|
106 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Maintenance · Stable
|
89 Participants
|
207 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 6 Maintenance · Improved
|
49 Participants
|
93 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Maintenance · Worsened
|
8 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Maintenance · Stable
|
152 Participants
|
293 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 6 Maintenance · Improved
|
41 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Maintenance · Worsened
|
21 Participants
|
50 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Maintenance · Stable
|
145 Participants
|
299 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 6 Maintenance · Improved
|
35 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 9 Maintenance · Worsened
|
22 Participants
|
76 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 9 Maintenance · Stable
|
100 Participants
|
167 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 9 Maintenance · Improved
|
68 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 9 Maintenance · Worsened
|
30 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 9 Maintenance · Stable
|
91 Participants
|
192 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 9 Maintenance · Improved
|
69 Participants
|
96 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 9 Maintenance · Worsened
|
41 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 9 Maintenance · Stable
|
71 Participants
|
140 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 9 Maintenance · Improved
|
78 Participants
|
145 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 9 Maintenance · Worsened
|
29 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 9 Maintenance · Stable
|
105 Participants
|
220 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 9 Maintenance · Improved
|
56 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 9 Maintenance · Worsened
|
57 Participants
|
113 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 9 Maintenance · Stable
|
102 Participants
|
183 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 9 Maintenance · Improved
|
31 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 9 Maintenance · Worsened
|
37 Participants
|
82 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 9 Maintenance · Improved
|
65 Participants
|
120 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 9 Maintenance · Worsened
|
52 Participants
|
101 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 9 Maintenance · Stable
|
114 Participants
|
234 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 9 Maintenance · Worsened
|
36 Participants
|
99 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 9 Maintenance · Stable
|
77 Participants
|
145 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 9 Maintenance · Worsened
|
37 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 9 Maintenance · Stable
|
119 Participants
|
223 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 9 Maintenance · Improved
|
34 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 9 Maintenance · Worsened
|
46 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 9 Maintenance · Stable
|
81 Participants
|
184 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 9 Maintenance · Improved
|
63 Participants
|
112 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 9 Maintenance · Worsened
|
14 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 15 Maintenance · Worsened
|
28 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 9 Maintenance · Stable
|
121 Participants
|
199 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 15 Maintenance · Improved
|
43 Participants
|
93 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 15 Maintenance · Worsened
|
13 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 15 Maintenance · Stable
|
89 Participants
|
164 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 15 Maintenance · Improved
|
50 Participants
|
92 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 15 Maintenance · Worsened
|
38 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 15 Maintenance · Stable
|
76 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 15 Maintenance · Improved
|
39 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 15 Maintenance · Worsened
|
12 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 15 Maintenance · Stable
|
116 Participants
|
200 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 15 Maintenance · Improved
|
25 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 15 Maintenance · Worsened
|
16 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 15 Maintenance · Stable
|
116 Participants
|
195 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 15 Maintenance · Improved
|
20 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 17 Maintenance · Worsened
|
4 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 17 Maintenance · Stable
|
24 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 17 Maintenance · Improved
|
12 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 17 Maintenance · Worsened
|
7 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 17 Maintenance · Stable
|
20 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 17 Maintenance · Improved
|
13 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 17 Maintenance · Worsened
|
10 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 17 Maintenance · Stable
|
14 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 17 Maintenance · Improved
|
16 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 17 Maintenance · Worsened
|
4 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 17 Maintenance · Stable
|
20 Participants
|
50 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 17 Maintenance · Improved
|
16 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 17 Maintenance · Worsened
|
13 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 17 Maintenance · Stable
|
21 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 17 Maintenance · Improved
|
6 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 17 Maintenance · Worsened
|
6 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 17 Maintenance · Stable
|
20 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 17 Maintenance · Improved
|
14 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 17 Maintenance · Worsened
|
6 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 17 Maintenance · Stable
|
14 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 17 Maintenance · Improved
|
20 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 17 Maintenance · Worsened
|
8 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 17 Maintenance · Stable
|
22 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 17 Maintenance · Improved
|
10 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 17 Maintenance · Worsened
|
8 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 17 Maintenance · Stable
|
13 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 17 Maintenance · Improved
|
19 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 17 Maintenance · Worsened
|
6 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 17 Maintenance · Stable
|
25 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 17 Maintenance · Improved
|
9 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 47 Maintenance · Stable
|
29 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 47 Maintenance · Improved
|
15 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 47 Maintenance · Worsened
|
18 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 47 Maintenance · Stable
|
24 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 47 Maintenance · Improved
|
6 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 47 Maintenance · Worsened
|
5 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 47 Maintenance · Stable
|
27 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 47 Maintenance · Improved
|
16 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 47 Maintenance · Worsened
|
7 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 47 Maintenance · Stable
|
11 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 47 Maintenance · Improved
|
30 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 47 Maintenance · Worsened
|
9 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 47 Maintenance · Stable
|
32 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 47 Maintenance · Improved
|
7 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 47 Maintenance · Worsened
|
11 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 47 Maintenance · Stable
|
18 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 47 Maintenance · Improved
|
19 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 47 Maintenance · Worsened
|
6 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 47 Maintenance · Stable
|
34 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 47 Maintenance · Improved
|
8 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 47 Maintenance · Worsened
|
11 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 47 Maintenance · Stable
|
23 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 47 Maintenance · Improved
|
14 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 47 Maintenance · Worsened
|
2 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 47 Maintenance · Stable
|
37 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 47 Maintenance · Improved
|
9 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 47 Maintenance · Worsened
|
13 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 47 Maintenance · Stable
|
25 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 47 Maintenance · Improved
|
10 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 47 Maintenance · Worsened
|
6 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 47 Maintenance · Stable
|
35 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 47 Maintenance · Improved
|
7 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 47 Maintenance · Worsened
|
6 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 47 Maintenance · Stable
|
37 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 47 Maintenance · Improved
|
5 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 53 Maintenance · Worsened
|
3 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 53 Maintenance · Stable
|
11 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 53 Maintenance · Improved
|
12 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 53 Maintenance · Worsened
|
4 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 53 Maintenance · Stable
|
11 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 53 Maintenance · Improved
|
11 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 53 Maintenance · Worsened
|
5 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 53 Maintenance · Stable
|
11 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 53 Maintenance · Improved
|
10 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 53 Maintenance · Worsened
|
3 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 53 Maintenance · Stable
|
17 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 53 Maintenance · Improved
|
6 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 53 Maintenance · Worsened
|
10 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 53 Maintenance · Stable
|
13 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 53 Maintenance · Improved
|
3 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 53 Maintenance · Worsened
|
7 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 53 Maintenance · Stable
|
12 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 53 Maintenance · Improved
|
7 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 53 Maintenance · Stable
|
7 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 53 Maintenance · Improved
|
16 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 17 Maintenance · Stable
|
19 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 17 Maintenance · Improved
|
13 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 17 Maintenance · Worsened
|
6 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 17 Maintenance · Stable
|
27 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 17 Maintenance · Improved
|
7 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 17 Maintenance · Worsened
|
6 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 17 Maintenance · Stable
|
22 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 17 Maintenance · Improved
|
12 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 17 Maintenance · Worsened
|
7 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 17 Maintenance · Stable
|
24 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 17 Maintenance · Improved
|
9 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 17 Maintenance · Worsened
|
7 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 17 Maintenance · Stable
|
26 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 17 Maintenance · Improved
|
7 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 23 Maintenance · Worsened
|
9 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 23 Maintenance · Stable
|
27 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 23 Maintenance · Improved
|
19 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 23 Maintenance · Worsened
|
10 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 23 Maintenance · Stable
|
29 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 23 Maintenance · Improved
|
16 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 23 Maintenance · Worsened
|
12 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 23 Maintenance · Stable
|
23 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 23 Maintenance · Improved
|
20 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 23 Maintenance · Worsened
|
10 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 23 Maintenance · Stable
|
33 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 23 Maintenance · Improved
|
12 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 23 Maintenance · Worsened
|
15 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 23 Maintenance · Stable
|
28 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 23 Maintenance · Improved
|
12 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 23 Maintenance · Worsened
|
12 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 23 Maintenance · Stable
|
31 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 23 Maintenance · Improved
|
12 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 23 Maintenance · Worsened
|
10 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 23 Maintenance · Stable
|
15 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 23 Maintenance · Improved
|
30 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 23 Maintenance · Worsened
|
8 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 23 Maintenance · Stable
|
36 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 23 Maintenance · Improved
|
11 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 23 Maintenance · Worsened
|
13 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 23 Maintenance · Stable
|
19 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 23 Maintenance · Improved
|
23 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 23 Maintenance · Worsened
|
7 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 23 Maintenance · Stable
|
37 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 23 Maintenance · Improved
|
11 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 23 Maintenance · Worsened
|
10 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 23 Maintenance · Stable
|
27 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 23 Maintenance · Improved
|
18 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 23 Maintenance · Worsened
|
6 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 23 Maintenance · Stable
|
40 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 23 Maintenance · Improved
|
9 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 23 Maintenance · Worsened
|
8 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 23 Maintenance · Stable
|
34 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 23 Maintenance · Improved
|
13 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 23 Maintenance · Worsened
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 23 Maintenance · Stable
|
41 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 23 Maintenance · Improved
|
10 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 23 Maintenance · Worsened
|
7 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 23 Maintenance · Stable
|
42 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 23 Maintenance · Improved
|
6 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 29 Maintenance · Worsened
|
5 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 29 Maintenance · Stable
|
27 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 29 Maintenance · Improved
|
20 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 29 Maintenance 20 · Worsened
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 29 Maintenance 20 · Stable
|
29 Participants
|
50 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 29 Maintenance 20 · Improved
|
19 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 29 Maintenance · Worsened
|
5 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 29 Maintenance · Stable
|
22 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 29 Maintenance · Improved
|
25 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 29 Maintenance · Worsened
|
5 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 29 Maintenance · Stable
|
32 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 29 Maintenance · Improved
|
15 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 29 Maintenance · Worsened
|
11 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 29 Maintenance · Stable
|
29 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 29 Maintenance · Improved
|
12 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 29 Maintenance · Worsened
|
12 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 29 Maintenance · Stable
|
20 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 29 Maintenance · Improved
|
20 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 29 Maintenance · Worsened
|
10 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 29 Maintenance · Stable
|
17 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 29 Maintenance · Improved
|
25 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 29 Maintenance · Worsened
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 29 Maintenance · Stable
|
37 Participants
|
64 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 29 Maintenance · Improved
|
11 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 29 Maintenance · Worsened
|
10 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 29 Maintenance · Stable
|
20 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 29 Maintenance · Improved
|
21 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 29 Maintenance · Worsened
|
9 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 29 Maintenance · Stable
|
30 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 29 Maintenance · Improved
|
12 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 29 Maintenance · Worsened
|
14 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 29 Maintenance · Stable
|
24 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 29 Maintenance · Improved
|
14 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 29 Maintenance · Worsened
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 29 Maintenance · Stable
|
37 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 29 Maintenance · Improved
|
11 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 29 Maintenance · Worsened
|
5 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 29 Maintenance · Stable
|
29 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 29 Maintenance · Improved
|
18 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 29 Maintenance · Worsened
|
3 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 29 Maintenance · Stable
|
39 Participants
|
76 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 29 Maintenance · Improved
|
10 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 29 Maintenance · Worsened
|
2 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 29 Maintenance · Stable
|
42 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 29 Maintenance · Improved
|
8 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 35 Maintenance · Worsened
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 35 Maintenance · Stable
|
24 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 35 Maintenance · Improved
|
16 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 35 Maintenance · Worsened
|
9 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 35 Maintenance · Stable
|
19 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 35 Maintenance · Improved
|
16 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 35 Maintenance · Worsened
|
6 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 35 Maintenance · Stable
|
21 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 35 Maintenance · Improved
|
17 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 35 Maintenance · Worsened
|
8 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 35 Maintenance · Stable
|
24 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 35 Maintenance · Improved
|
12 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 35 Maintenance · Worsened
|
15 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 35 Maintenance · Stable
|
23 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 35 Maintenance · Improved
|
6 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 35 Maintenance · Worsened
|
11 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 35 Maintenance · Stable
|
21 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 35 Maintenance · Improved
|
12 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 35 Maintenance · Worsened
|
10 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 35 Maintenance · Stable
|
10 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 35 Maintenance · Improved
|
24 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 35 Maintenance · Worsened
|
6 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 35 Maintenance · Stable
|
33 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 35 Maintenance · Improved
|
5 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 35 Maintenance · Worsened
|
6 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 35 Maintenance · Stable
|
19 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 35 Maintenance · Improved
|
19 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 35 Maintenance · Worsened
|
8 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 35 Maintenance · Stable
|
30 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 35 Maintenance · Improved
|
6 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 35 Maintenance · Worsened
|
15 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 35 Maintenance · Stable
|
20 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 35 Maintenance · Improved
|
9 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 35 Maintenance · Worsened
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 35 Maintenance · Stable
|
36 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 35 Maintenance · Improved
|
5 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 35 Maintenance · Worsened
|
5 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 35 Maintenance · Stable
|
27 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 35 Maintenance · Improved
|
12 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 53 Maintenance · Worsened
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 35 Maintenance · Worsened
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 35 Maintenance · Stable
|
35 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 35 Maintenance · Improved
|
5 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 35 Maintenance · Worsened
|
6 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 35 Maintenance · Stable
|
30 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 35 Maintenance · Improved
|
8 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 41 Maintenance · Worsened
|
10 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 53 Maintenance · Stable
|
19 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 41 Maintenance · Stable
|
26 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 41 Maintenance · Improved
|
22 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 41 Maintenance · Worsened
|
5 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 41 Maintenance · Stable
|
32 Participants
|
54 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 41 Maintenance · Improved
|
21 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 41 Maintenance · Worsened
|
9 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 41 Maintenance · Stable
|
25 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 41 Maintenance · Improved
|
24 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 41 Maintenance · Worsened
|
10 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 53 Maintenance · Improved
|
4 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 53 Maintenance · Worsened
|
4 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 41 Maintenance · Stable
|
35 Participants
|
55 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 41 Maintenance · Improved
|
13 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 41 Maintenance · Worsened
|
23 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 41 Maintenance · Stable
|
25 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 53 Maintenance · Stable
|
12 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 53 Maintenance · Improved
|
10 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 41 Maintenance · Improved
|
10 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 53 Maintenance · Worsened
|
3 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 41 Maintenance · Worsened
|
13 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 41 Maintenance · Stable
|
25 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 41 Maintenance · Improved
|
20 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 41 Maintenance · Worsened
|
11 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 41 Maintenance · Stable
|
17 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 53 Maintenance · Stable
|
18 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 41 Maintenance · Improved
|
30 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 41 Maintenance · Worsened
|
8 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 41 Maintenance · Stable
|
39 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 41 Maintenance · Improved
|
11 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 41 Maintenance · Worsened
|
11 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 41 Maintenance · Stable
|
23 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 53 Maintenance · Improved
|
5 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 53 Maintenance · Worsened
|
8 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 53 Maintenance · Stable
|
13 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 41 Maintenance · Improved
|
24 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 41 Maintenance · Worsened
|
8 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 41 Maintenance · Stable
|
39 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 41 Maintenance · Improved
|
11 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 41 Maintenance · Worsened
|
16 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 53 Maintenance · Improved
|
5 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 53 Maintenance · Worsened
|
2 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 53 Maintenance · Stable
|
22 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 41 Maintenance · Stable
|
25 Participants
|
52 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 41 Maintenance · Improved
|
17 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 41 Maintenance · Worsened
|
9 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 41 Maintenance · Stable
|
38 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 41 Maintenance · Improved
|
11 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 41 Maintenance · Worsened
|
12 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 53 Maintenance · Worsened
|
7 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 53 Maintenance · Stable
|
14 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 53 Maintenance · Improved
|
5 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 41 Maintenance · Stable
|
33 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 41 Maintenance · Improved
|
13 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 41 Maintenance · Worsened
|
5 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 53 Maintenance · Worsened
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 41 Maintenance · Stable
|
44 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 53 Maintenance · Stable
|
20 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 53 Maintenance · Improved
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 53 Maintenance · Worsened
|
6 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 53 Maintenance · Stable
|
16 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 53 Maintenance · Improved
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 59 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 59 Maintenance · Improved
|
6 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 59 Maintenance · Worsened
|
3 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 59 Maintenance · Stable
|
8 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 59 Maintenance · Improved
|
7 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 59 Maintenance · Worsened
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 59 Maintenance · Stable
|
8 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 59 Maintenance · Improved
|
7 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 59 Maintenance · Worsened
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 59 Maintenance · Stable
|
11 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 59 Maintenance · Improved
|
3 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 59 Maintenance · Worsened
|
5 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 59 Maintenance · Stable
|
11 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 41 Maintenance · Improved
|
9 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 41 Maintenance · Worsened
|
8 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 41 Maintenance · Stable
|
42 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 41 Maintenance · Improved
|
8 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 47 Maintenance · Worsened
|
5 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 47 Maintenance · Stable
|
26 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 47 Maintenance · Improved
|
17 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 47 Maintenance · Worsened
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 47 Maintenance · Stable
|
30 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 47 Maintenance · Improved
|
14 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 47 Maintenance · Worsened
|
8 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 47 Maintenance · Stable
|
23 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 47 Maintenance · Improved
|
17 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 47 Maintenance · Worsened
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 59 Maintenance · Improved
|
2 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 59 Maintenance · Worsened
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 59 Maintenance · Stable
|
10 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 59 Maintenance · Worsened
|
4 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 59 Maintenance · Stable
|
8 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 59 Maintenance · Improved
|
6 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 59 Maintenance · Worsened
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 59 Maintenance · Stable
|
12 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 59 Maintenance · Improved
|
2 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 59 Maintenance · Worsened
|
1 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 59 Maintenance · Improved
|
7 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 59 Maintenance · Worsened
|
2 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 59 Maintenance · Stable
|
12 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 59 Maintenance · Improved
|
4 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 59 Maintenance · Worsened
|
6 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 59 Maintenance · Stable
|
10 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 59 Maintenance · Improved
|
2 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 59 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 59 Maintenance · Stable
|
16 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 59 Maintenance · Improved
|
1 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 59 Maintenance · Worsened
|
5 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 59 Maintenance · Stable
|
12 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 59 Maintenance · Improved
|
1 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 59 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 59 Maintenance · Stable
|
14 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 59 Maintenance · Worsened
|
3 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 59 Maintenance · Improved
|
4 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 65 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 65 Maintenance · Stable
|
7 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 65 Maintenance · Improved
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 65 Maintenance · Worsened
|
1 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 65 Maintenance · Stable
|
6 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 65 Maintenance · Improved
|
5 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 65 Maintenance · Worsened
|
2 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 65 Maintenance · Stable
|
4 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 65 Maintenance · Improved
|
6 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 65 Maintenance · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 65 Maintenance · Stable
|
8 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 65 Maintenance · Improved
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 65 Maintenance · Worsened
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 65 Maintenance · Stable
|
7 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 65 Maintenance · Improved
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 65 Maintenance · Stable
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 65 Maintenance · Improved
|
4 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 65 Maintenance · Worsened
|
1 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 65 Maintenance · Stable
|
5 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 65 Maintenance · Improved
|
6 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 65 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 65 Maintenance · Stable
|
9 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 65 Maintenance · Improved
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 65 Maintenance · Worsened
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 65 Maintenance · Stable
|
7 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 65 Maintenance · Improved
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 65 Maintenance · Worsened
|
2 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 65 Maintenance · Stable
|
9 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 65 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 65 Maintenance · Worsened
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 65 Maintenance · Stable
|
7 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 65 Maintenance · Improved
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 65 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 65 Maintenance · Stable
|
11 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 65 Maintenance · Improved
|
1 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 65 Maintenance · Worsened
|
6 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 65 Maintenance · Stable
|
5 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 65 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 65 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 65 Maintenance · Stable
|
10 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 65 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 65 Maintenance · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 65 Maintenance · Stable
|
8 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 65 Maintenance · Improved
|
3 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 71 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 71 Maintenance · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 71 Maintenance · Improved
|
5 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 71 Maintenance · Worsened
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 71 Maintenance · Stable
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 71 Maintenance · Improved
|
3 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 71 Maintenance · Worsened
|
0 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 71 Maintenance · Stable
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 71 Maintenance · Improved
|
4 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 71 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 71 Maintenance · Stable
|
6 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 71 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 71 Maintenance · Worsened
|
3 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 71 Maintenance · Stable
|
5 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 71 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 71 Maintenance · Worsened
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 71 Maintenance · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 71 Maintenance · Improved
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 71 Maintenance · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 71 Maintenance · Stable
|
3 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 71 Maintenance · Improved
|
5 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 71 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 71 Maintenance · Stable
|
5 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 71 Maintenance · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 71 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 71 Maintenance · Stable
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 71 Maintenance · Improved
|
4 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 71 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 71 Maintenance · Stable
|
7 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 71 Maintenance · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 71 Maintenance · Worsened
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 71 Maintenance · Stable
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 71 Maintenance · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 71 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 71 Maintenance · Stable
|
6 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 71 Maintenance · Improved
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 71 Maintenance · Worsened
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 71 Maintenance · Stable
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 71 Maintenance · Improved
|
2 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 71 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 71 Maintenance · Stable
|
7 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 71 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 71 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 71 Maintenance · Stable
|
4 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 71 Maintenance · Improved
|
3 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 77 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 77 Maintenance · Stable
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 77 Maintenance · Improved
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 77 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 77 Maintenance · Stable
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 77 Maintenance · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 77 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 77 Maintenance · Stable
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 77 Maintenance · Improved
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 77 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 77 Maintenance · Stable
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 77 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 77 Maintenance · Stable
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 77 Maintenance · Improved
|
1 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 77 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 77 Maintenance · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 77 Maintenance · Improved
|
2 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 77 Maintenance · Worsened
|
0 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 77 Maintenance · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 77 Maintenance · Improved
|
3 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 77 Maintenance · Stable
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 77 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 77 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 77 Maintenance · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 77 Maintenance · Improved
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 77 Maintenance · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 77 Maintenance · Stable
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 77 Maintenance · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 77 Maintenance · Worsened
|
0 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 77 Maintenance · Stable
|
3 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 77 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 77 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 77 Maintenance · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 77 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 77 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 77 Maintenance · Stable
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 77 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 77 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 77 Maintenance · Stable
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 77 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 77 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 77 Maintenance · Stable
|
2 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 77 Maintenance · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 83 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 83 Maintenance · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 83 Maintenance · Improved
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 83 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 83 Maintenance · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 83 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 83 Maintenance · Stable
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 83 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 83 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 83 Maintenance · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 83 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 83 Maintenance · Stable
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 83 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 83 Maintenance · Stable
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 83 Maintenance · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 83 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 83 Maintenance · Stable
|
3 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 83 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 83 Maintenance · Stable
|
3 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 83 Maintenance · Worsened
|
2 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 83 Maintenance · Stable
|
0 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 83 Maintenance · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 83 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 83 Maintenance · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 83 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 83 Maintenance · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 83 Maintenance · Stable
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 83 Maintenance · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, End of treatment (EOT) · Worsened
|
50 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, End of treatment (EOT) · Stable
|
81 Participants
|
150 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, EOT · Worsened
|
44 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, EOT · Stable
|
80 Participants
|
161 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, EOT · Worsened
|
57 Participants
|
102 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, EOT · Stable
|
64 Participants
|
115 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, EOT · Worsened
|
68 Participants
|
127 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, EOT · Stable
|
92 Participants
|
155 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, EOT · Improved
|
24 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, EOT · Worsened
|
58 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, EOT · Stable
|
68 Participants
|
118 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, EOT · Improved
|
58 Participants
|
108 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, EOT · Worsened
|
66 Participants
|
124 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, EOT · Stable
|
45 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, EOT · Improved
|
73 Participants
|
140 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, EOT · Worsened
|
38 Participants
|
72 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, EOT · Stable
|
117 Participants
|
204 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, EOT · Improved
|
29 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, EOT · Worsened
|
66 Participants
|
95 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, EOT · Stable
|
50 Participants
|
140 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, EOT · Improved
|
68 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, EOT · Worsened
|
47 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, EOT · Stable
|
109 Participants
|
185 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, EOT · Improved
|
28 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, EOT · Worsened
|
47 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, EOT · Stable
|
81 Participants
|
160 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, EOT · Improved
|
56 Participants
|
93 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, EOT · Worsened
|
40 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, EOT · Stable
|
94 Participants
|
188 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, EOT · Improved
|
49 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, EOT · Worsened
|
44 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, EOT · Stable
|
89 Participants
|
172 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, EOT · Improved
|
50 Participants
|
98 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, EOT · Worsened
|
24 Participants
|
61 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, EOT · Stable
|
127 Participants
|
225 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, EOT · Improved
|
33 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, EOT · Worsened
|
28 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, EOT · Stable
|
130 Participants
|
239 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, EOT · Improved
|
25 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Safety Follow-up · Worsened
|
36 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Safety Follow-up · Stable
|
71 Participants
|
130 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, Safety Follow-up · Improved
|
39 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Safety Follow-up · Worsened
|
40 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Safety Follow-up · Stable
|
66 Participants
|
129 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, Safety Follow-up · Improved
|
40 Participants
|
78 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Safety Follow-up · Worsened
|
46 Participants
|
99 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Safety Follow-up · Stable
|
55 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, Safety Follow-up · Improved
|
45 Participants
|
102 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Safety Follow-up · Worsened
|
44 Participants
|
107 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Safety Follow-up · Stable
|
72 Participants
|
147 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, Safety Follow-up · Improved
|
30 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Safety Follow-up · Worsened
|
56 Participants
|
112 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Safety Follow-up · Stable
|
69 Participants
|
119 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, Safety Follow-up · Improved
|
21 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Safety Follow-up · Worsened
|
42 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Safety Follow-up · Stable
|
59 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, Safety Follow-up · Improved
|
45 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Safety Follow-up · Worsened
|
54 Participants
|
109 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Safety Follow-up · Stable
|
31 Participants
|
75 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, Safety Follow-up · Improved
|
61 Participants
|
106 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Safety Follow-up · Worsened
|
34 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Safety Follow-up · Stable
|
92 Participants
|
169 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, Safety Follow-up · Improved
|
20 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Safety Follow-up · Worsened
|
50 Participants
|
108 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Safety Follow-up · Stable
|
47 Participants
|
101 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, Safety Follow-up · Improved
|
49 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Safety Follow-up · Worsened
|
36 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Safety Follow-up · Stable
|
91 Participants
|
158 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, Safety Follow-up · Improved
|
19 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Safety Follow-up · Worsened
|
22 Participants
|
79 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Safety Follow-up · Stable
|
75 Participants
|
132 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, Safety Follow-up · Improved
|
49 Participants
|
79 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Safety Follow-up · Worsened
|
28 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Safety Follow-up · Stable
|
81 Participants
|
140 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, Safety Follow-up · Improved
|
37 Participants
|
75 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Safety Follow-up · Worsened
|
32 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Safety Follow-up · Stable
|
72 Participants
|
153 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, Safety Follow-up · Improved
|
41 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Safety Follow-up · Worsened
|
21 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Safety Follow-up · Stable
|
97 Participants
|
184 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, Safety Follow-up · Improved
|
27 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Safety Follow-up · Worsened
|
19 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Safety Follow-up · Stable
|
114 Participants
|
199 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, Safety Follow-up · Improved
|
12 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 3 months) · Worsened
|
39 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 3 months) · Stable
|
53 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 3 months) · Improved
|
43 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 3 months) · Worsened
|
42 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 3 months) · Stable
|
66 Participants
|
100 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 3 months) · Improved
|
27 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 3 months) · Worsened
|
52 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 3 months) · Stable
|
42 Participants
|
84 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 3 months) · Improved
|
41 Participants
|
95 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 3 months) · Worsened
|
30 Participants
|
76 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 3 months) · Stable
|
76 Participants
|
129 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 3 months) · Improved
|
29 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 3 months) · Worsened
|
55 Participants
|
96 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 3 months) · Stable
|
64 Participants
|
110 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 3 months) · Improved
|
16 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 3 months) · Worsened
|
48 Participants
|
80 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 3 months) · Stable
|
51 Participants
|
91 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 3 months) · Improved
|
36 Participants
|
79 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 3 months) · Worsened
|
52 Participants
|
98 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 3 months) · Stable
|
28 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 3 months) · Improved
|
55 Participants
|
94 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 3 months) · Worsened
|
20 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 3 months) · Stable
|
88 Participants
|
155 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 3 months) · Improved
|
27 Participants
|
50 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 3 months) · Worsened
|
41 Participants
|
89 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 3 months) · Stable
|
42 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 3 months) · Improved
|
52 Participants
|
74 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 3 months) · Worsened
|
33 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 3 months) · Stable
|
84 Participants
|
141 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 3 months) · Improved
|
18 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 3 months) · Worsened
|
28 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 3 months) · Stable
|
66 Participants
|
111 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 3 months) · Improved
|
40 Participants
|
81 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 3 months) · Worsened
|
25 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 3 months) · Stable
|
75 Participants
|
130 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 3 months) · Improved
|
35 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 3 months) · Worsened
|
25 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 3 months) · Stable
|
64 Participants
|
128 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 3 months) · Improved
|
45 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 3 months) · Worsened
|
20 Participants
|
52 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 3 months) · Stable
|
89 Participants
|
157 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 3 months) · Improved
|
26 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 3 months) · Worsened
|
24 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 3 months) · Stable
|
90 Participants
|
169 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 3 months) · Improved
|
21 Participants
|
38 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 9 months) · Worsened
|
24 Participants
|
60 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 9 months) · Stable
|
53 Participants
|
77 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 9 months) · Improved
|
29 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 9 months) · Worsened
|
32 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 9 months) · Stable
|
59 Participants
|
83 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 9 months) · Improved
|
14 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 9 months) · Worsened
|
37 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 9 months) · Stable
|
37 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 9 months) · Improved
|
32 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 9 months) · Worsened
|
31 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 9 months) · Stable
|
57 Participants
|
97 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 9 months) · Improved
|
18 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 9 months) · Worsened
|
42 Participants
|
65 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 9 months) · Stable
|
55 Participants
|
89 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 9 months) · Improved
|
9 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 9 months) · Worsened
|
40 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 9 months) · Stable
|
37 Participants
|
69 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 9 months) · Improved
|
29 Participants
|
53 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 9 months) · Worsened
|
43 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 9 months) · Stable
|
22 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 9 months) · Improved
|
41 Participants
|
64 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 9 months) · Worsened
|
21 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 9 months) · Stable
|
68 Participants
|
112 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 9 months) · Improved
|
17 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 9 months) · Worsened
|
33 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 9 months) · Stable
|
46 Participants
|
59 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 9 months) · Improved
|
27 Participants
|
55 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 9 months) · Stable
|
59 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 9 months) · Improved
|
13 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 9 months) · Worsened
|
24 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 9 months) · Stable
|
55 Participants
|
82 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 9 months) · Improved
|
27 Participants
|
57 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 9 months) · Worsened
|
21 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 9 months) · Stable
|
59 Participants
|
93 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 9 months) · Improved
|
25 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 9 months) · Worsened
|
23 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 9 months) · Stable
|
50 Participants
|
85 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 9 months) · Improved
|
33 Participants
|
54 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 9 months) · Worsened
|
21 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 9 months) · Stable
|
65 Participants
|
122 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 9 months) · Improved
|
20 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 9 months) · Worsened
|
18 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 9 months) · Stable
|
67 Participants
|
129 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 9 months) · Improved
|
21 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 15 months) · Worsened
|
23 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 15 months) · Stable
|
34 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 15 months) · Improved
|
19 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 15 months) · Worsened
|
23 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 15 months) · Stable
|
38 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 15 months) · Improved
|
13 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 15 months) · Worsened
|
29 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 15 months) · Stable
|
22 Participants
|
66 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 15 months) · Improved
|
25 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 15 months) · Worsened
|
23 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 15 months) · Stable
|
42 Participants
|
86 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 15 months) · Improved
|
11 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 15 months) · Worsened
|
23 Participants
|
55 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 15 months) · Stable
|
43 Participants
|
70 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 15 months) · Improved
|
10 Participants
|
29 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 15 months) · Worsened
|
31 Participants
|
51 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 15 months) · Stable
|
23 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 15 months) · Improved
|
22 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 15 months) · Worsened
|
29 Participants
|
63 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 15 months) · Stable
|
14 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 15 months) · Improved
|
33 Participants
|
52 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 15 months) · Worsened
|
19 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 15 months) · Stable
|
49 Participants
|
101 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 15 months) · Improved
|
8 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 15 months) · Worsened
|
21 Participants
|
61 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 15 months) · Stable
|
30 Participants
|
54 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 15 months) · Improved
|
25 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 15 months) · Worsened
|
24 Participants
|
47 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 15 months) · Stable
|
43 Participants
|
82 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 15 months) · Improved
|
9 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 15 months) · Worsened
|
19 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 15 months) · Stable
|
32 Participants
|
71 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 15 months) · Improved
|
24 Participants
|
48 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 15 months) · Worsened
|
13 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 15 months) · Stable
|
40 Participants
|
87 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 15 months) · Improved
|
23 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 15 months) · Worsened
|
20 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 15 months) · Stable
|
35 Participants
|
73 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 15 months) · Improved
|
21 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 15 months) · Worsened
|
12 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 15 months) · Stable
|
52 Participants
|
103 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 15 months) · Improved
|
12 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 15 months) · Worsened
|
9 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 15 months) · Stable
|
54 Participants
|
105 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 15 months) · Improved
|
13 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 21 months) · Worsened
|
19 Participants
|
36 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 21 months) · Stable
|
14 Participants
|
37 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 21 months) · Improved
|
15 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 21 months) · Worsened
|
15 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 21 months) · Stable
|
25 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 21 months) · Improved
|
8 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 21 months) · Worsened
|
15 Participants
|
35 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 21 months) · Stable
|
16 Participants
|
30 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 21 months) · Improved
|
17 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 21 months) · Worsened
|
16 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 21 months) · Stable
|
28 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 21 months) · Improved
|
4 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 21 months) · Worsened
|
18 Participants
|
40 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 21 months) · Stable
|
24 Participants
|
39 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 21 months) · Improved
|
6 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 21 months) · Worsened
|
13 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 21 months) · Stable
|
20 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 21 months) · Improved
|
15 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 21 months) · Worsened
|
22 Participants
|
42 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 21 months) · Stable
|
9 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 21 months) · Improved
|
17 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 21 months) · Worsened
|
13 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 21 months) · Stable
|
28 Participants
|
61 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 21 months) · Improved
|
7 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 21 months) · Worsened
|
16 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 21 months) · Stable
|
14 Participants
|
34 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 21 months) · Improved
|
18 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 21 months) · Worsened
|
18 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 21 months) · Stable
|
24 Participants
|
58 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 21 months) · Improved
|
6 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 21 months) · Worsened
|
14 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 21 months) · Stable
|
22 Participants
|
41 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 21 months) · Improved
|
12 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 21 months) · Worsened
|
11 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 21 months) · Stable
|
24 Participants
|
56 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 21 months) · Improved
|
13 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 21 months) · Worsened
|
8 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 21 months) · Stable
|
22 Participants
|
45 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 21 months) · Improved
|
18 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 21 months) · Worsened
|
12 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 21 months) · Stable
|
32 Participants
|
62 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 21 months) · Improved
|
4 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 21 months) · Worsened
|
5 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 21 months) · Stable
|
33 Participants
|
68 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 21 months) · Improved
|
9 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 27 months) · Worsened
|
9 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 27 months) · Stable
|
15 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 27 months) · Improved
|
12 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 27 months) · Worsened
|
13 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 27 months) · Stable
|
16 Participants
|
32 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 27 months) · Improved
|
7 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 27 months) · Worsened
|
9 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 27 months) · Stable
|
13 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 27 months) · Improved
|
14 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 27 months) · Worsened
|
9 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 27 months) · Stable
|
21 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 27 months) · Improved
|
6 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 27 months) · Worsened
|
12 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 27 months) · Stable
|
16 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 27 months) · Improved
|
8 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 27 months) · Worsened
|
14 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 27 months) · Stable
|
11 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 27 months) · Improved
|
11 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 27 months) · Worsened
|
14 Participants
|
25 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 27 months) · Stable
|
7 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 27 months) · Improved
|
15 Participants
|
27 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 27 months) · Worsened
|
7 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 27 months) · Stable
|
25 Participants
|
46 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 27 months) · Improved
|
4 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 27 months) · Worsened
|
9 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 27 months) · Stable
|
13 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 27 months) · Improved
|
14 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 27 months) · Worsened
|
11 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 27 months) · Stable
|
19 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 27 months) · Improved
|
6 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 27 months) · Worsened
|
8 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 27 months) · Stable
|
18 Participants
|
31 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 27 months) · Improved
|
10 Participants
|
23 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 27 months) · Worsened
|
9 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 27 months) · Stable
|
16 Participants
|
44 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 27 months) · Improved
|
11 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 27 months) · Worsened
|
5 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 27 months) · Stable
|
17 Participants
|
33 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 27 months) · Improved
|
14 Participants
|
22 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 27 months) · Worsened
|
8 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 27 months) · Stable
|
25 Participants
|
43 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 27 months) · Improved
|
3 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 27 months) · Worsened
|
4 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 27 months) · Stable
|
25 Participants
|
49 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 27 months) · Improved
|
7 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 33 months) · Worsened
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 33 months) · Stable
|
6 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 33 months) · Improved
|
6 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 33 months) · Stable
|
9 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 33 months) · Improved
|
2 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 33 months) · Worsened
|
4 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 33 months) · Stable
|
8 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 33 months) · Improved
|
4 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 33 months) · Stable
|
8 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 33 months) · Improved
|
3 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 33 months) · Stable
|
9 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 33 months) · Improved
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 33 months) · Stable
|
6 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 33 months) · Improved
|
5 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 33 months) · Stable
|
2 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 33 months) · Improved
|
9 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 33 months) · Worsened
|
4 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 33 months) · Stable
|
11 Participants
|
24 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 33 months) · Improved
|
1 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 33 months) · Worsened
|
2 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 33 months) · Stable
|
7 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 33 months) · Improved
|
7 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 33 months) · Stable
|
9 Participants
|
21 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 33 months) · Improved
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 33 months) · Worsened
|
3 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 33 months) · Stable
|
9 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 33 months) · Improved
|
4 Participants
|
17 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 33 months) · Worsened
|
6 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 33 months) · Stable
|
7 Participants
|
28 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 33 months) · Improved
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 33 months) · Worsened
|
2 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 33 months) · Stable
|
7 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 33 months) · Improved
|
7 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 33 months) · Worsened
|
5 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 33 months) · Stable
|
10 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 33 months) · Improved
|
1 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 33 months) · Worsened
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 33 months) · Stable
|
10 Participants
|
26 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 33 months) · Improved
|
4 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
14 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 39 months) · Improved
|
5 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 39 months) · Worsened
|
2 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 39 months) · Stable
|
6 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 39 months) · Worsened
|
0 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 39 months) · Stable
|
7 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 39 months) · Improved
|
4 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 39 months) · Worsened
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 39 months) · Stable
|
7 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 39 months) · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 39 months) · Worsened
|
4 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 39 months) · Stable
|
5 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 39 months) · Improved
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 39 months) · Worsened
|
1 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 39 months) · Stable
|
4 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 39 months) · Improved
|
6 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 39 months) · Worsened
|
1 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 39 months) · Improved
|
7 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 39 months) · Stable
|
8 Participants
|
19 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 39 months) · Improved
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 39 months) · Worsened
|
4 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 39 months) · Stable
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 39 months) · Worsened
|
5 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
15 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 39 months) · Worsened
|
5 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
13 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 39 months) · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 39 months) · Stable
|
7 Participants
|
20 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 39 months) · Worsened
|
2 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 39 months) · Stable
|
5 Participants
|
10 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 57 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 57 months) · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 57 months) · Improved
|
2 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 63 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 63 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 51 months) · Stable
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 51 months) · Improved
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 57 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 39 months) · Improved
|
4 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 39 months) · Worsened
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 39 months) · Stable
|
8 Participants
|
16 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 39 months) · Improved
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 39 months) · Stable
|
6 Participants
|
18 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 39 months) · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 45 months) · Stable
|
4 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 45 months) · Improved
|
0 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 45 months) · Stable
|
3 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 45 months) · Stable
|
4 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 45 months) · Improved
|
0 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 45 months) · Stable
|
4 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 45 months) · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
6 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
9 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 45 months) · Worsened
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
8 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
12 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
AL, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Constipation, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 45 months) · Stable
|
3 Participants
|
7 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Diarrhoea, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 45 months) · Stable
|
1 Participants
|
11 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
FD, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 51 months) · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
GHS/QoL, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 51 months) · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
PF, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
RF, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
EF, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 51 months) · Stable
|
2 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
CF, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
SF, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Fatigue, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 51 months) · Stable
|
2 Participants
|
5 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
N/V, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Pain, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 51 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
4 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Dyspnoea, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Improvement and Worsening in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC-QLQ-C30)
Insomnia, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
3 Participants
|
SECONDARY outcome
Timeframe: Day1 of Chemo Cycles 2(baseline), 4&6; Day1 of Maintenance Cycles 1,2,3,6,9,12,15,17,23,29,35,41,47,53,59,65,71,77,83,89; EOT visit up to a maximum of 63 months; LTFU visit up to a maximum of 69 months(including SFU visit up to a maximum of 61 months)Population: ITT Population.Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified timepoints. As pre-specified in the protocol, the comparison of data was performed only between Arm 2 and Arm 3.
The EORTC QLQ-OV28 supplements the QLQ-C30. It includes three functional scales (body image (BI), sexuality (S), attitude to disease/treatment(ATD)) and five symptom scales/items (abdominal/GI symptoms (AS), peripheral neuropathy (PN), hormonal/menopausal symptoms (MS), other chemotherapy side effects (CSE), and hair loss (HS)). Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much). Higher scores represent better functioning (better quality of life). For functional scales: improved (worsened) is defined as \>=10 points increase (decrease) from baseline. For symptom scales: improved (worsened) is defined as \>=10 points decrease (increase) from baseline. Baseline is defined as the latest, non-missing collected value, excluding end of treatment, safety follow-up, long term follow-up visits records and unscheduled visits after end of treatment.
Outcome measures
| Measure |
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=331 Participants
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=657 Participants
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy.
Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision
|
|---|---|---|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 15 Maintenance · Stable
|
40 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 17 Maintenance · Stable
|
18 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 17 Maintenance · Stable
|
19 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 17 Maintenance · Improved
|
14 Participants
|
36 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 17 Maintenance · Worsened
|
19 Participants
|
45 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 29 Maintenance · Stable
|
30 Participants
|
54 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 47 Maintenance · Stable
|
18 Participants
|
34 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 47 Maintenance · Improved
|
15 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 45 months) · Worsened
|
3 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 51 months) · Stable
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 51 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 57 months) · Worsened
|
2 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 57 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 57 months) · Stable
|
2 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 57 months) · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 63 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 33 months) · Stable
|
8 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 33 months) · Improved
|
6 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 4 Chemotherapy · Worsened
|
89 Participants
|
214 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 4 Chemotherapy · Stable
|
108 Participants
|
189 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 4 Chemotherapy · Improved
|
73 Participants
|
131 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 4 Chemotherapy · Worsened
|
30 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 4 Chemotherapy · Stable
|
188 Participants
|
390 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 4 Chemotherapy · Improved
|
51 Participants
|
77 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 4 Chemotherapy · Worsened
|
103 Participants
|
205 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 4 Chemotherapy · Stable
|
91 Participants
|
148 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 4 Chemotherapy · Improved
|
76 Participants
|
181 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 4 Chemotherapy · Worsened
|
40 Participants
|
81 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 4 Chemotherapy · Stable
|
166 Participants
|
325 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 4 Chemotherapy · Improved
|
70 Participants
|
129 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 4 Chemotherapy · Worsened
|
151 Participants
|
316 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 4 Chemotherapy · Stable
|
68 Participants
|
135 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 4 Chemotherapy · Improved
|
57 Participants
|
84 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 4 Chemotherapy · Worsened
|
68 Participants
|
153 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 4 Chemotherapy · Stable
|
135 Participants
|
255 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 4 Chemotherapy · Improved
|
73 Participants
|
127 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 4 Chemotherapy · Worsened
|
88 Participants
|
168 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 4 Chemotherapy · Stable
|
145 Participants
|
278 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 4 Chemotherapy · Improved
|
43 Participants
|
89 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 4 Chemotherapy · Worsened
|
92 Participants
|
176 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 4 Chemotherapy · Stable
|
81 Participants
|
139 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 4 Chemotherapy · Improved
|
100 Participants
|
219 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Chemotherapy · Worsened
|
99 Participants
|
216 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Chemotherapy · Stable
|
97 Participants
|
168 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Chemotherapy · Improved
|
70 Participants
|
148 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Chemotherapy · Worsened
|
29 Participants
|
71 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Chemotherapy · Stable
|
184 Participants
|
368 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Chemotherapy · Improved
|
48 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Chemotherapy · Worsened
|
87 Participants
|
218 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Chemotherapy · Stable
|
81 Participants
|
132 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Chemotherapy · Improved
|
97 Participants
|
182 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Chemotherapy · Worsened
|
32 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Chemotherapy · Stable
|
148 Participants
|
312 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Chemotherapy · Improved
|
87 Participants
|
156 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Chemotherapy · Worsened
|
175 Participants
|
371 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Chemotherapy · Stable
|
50 Participants
|
99 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Chemotherapy · Improved
|
42 Participants
|
63 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Chemotherapy · Worsened
|
71 Participants
|
161 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Chemotherapy · Stable
|
113 Participants
|
240 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Chemotherapy · Improved
|
83 Participants
|
132 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Chemotherapy · Worsened
|
77 Participants
|
173 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Chemotherapy · Stable
|
144 Participants
|
279 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Chemotherapy · Improved
|
46 Participants
|
80 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Chemotherapy · Worsened
|
106 Participants
|
181 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Chemotherapy · Stable
|
60 Participants
|
121 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Chemotherapy · Improved
|
100 Participants
|
230 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 1 Maintenance · Worsened
|
95 Participants
|
187 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 1 Maintenance · Stable
|
92 Participants
|
165 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 1 Maintenance · Improved
|
75 Participants
|
142 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 1 Maintenance · Worsened
|
29 Participants
|
63 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 1 Maintenance · Stable
|
172 Participants
|
337 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 1 Maintenance · Improved
|
53 Participants
|
85 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 1 Maintenance · Worsened
|
104 Participants
|
181 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 1 Maintenance · Stable
|
73 Participants
|
143 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 1 Maintenance · Improved
|
85 Participants
|
170 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 1 Maintenance · Worsened
|
25 Participants
|
55 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 1 Maintenance · Stable
|
152 Participants
|
284 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 1 Maintenance · Improved
|
85 Participants
|
157 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 1 Maintenance · Worsened
|
173 Participants
|
358 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 1 Maintenance · Stable
|
49 Participants
|
73 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 1 Maintenance · Improved
|
40 Participants
|
64 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 1 Maintenance · Worsened
|
68 Participants
|
127 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 1 Maintenance · Stable
|
115 Participants
|
239 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 1 Maintenance · Improved
|
79 Participants
|
130 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 1 Maintenance · Worsened
|
66 Participants
|
162 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 1 Maintenance · Stable
|
151 Participants
|
235 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 1 Maintenance · Improved
|
45 Participants
|
98 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 1 Maintenance · Worsened
|
89 Participants
|
145 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 1 Maintenance · Stable
|
56 Participants
|
117 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 1 Maintenance · Improved
|
115 Participants
|
232 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 2 Maintenance · Worsened
|
74 Participants
|
162 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 2 Maintenance · Stable
|
85 Participants
|
143 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 2 Maintenance · Improved
|
68 Participants
|
124 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 2 Maintenance · Worsened
|
16 Participants
|
53 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 2 Maintenance · Stable
|
166 Participants
|
290 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 2 Maintenance · Improved
|
38 Participants
|
74 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 2 Maintenance · Worsened
|
75 Participants
|
156 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 2 Maintenance · Stable
|
54 Participants
|
103 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 2 Maintenance · Improved
|
98 Participants
|
169 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 2 Maintenance · Worsened
|
19 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 2 Maintenance · Stable
|
127 Participants
|
260 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 2 Maintenance · Improved
|
82 Participants
|
136 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 2 Maintenance · Worsened
|
128 Participants
|
277 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 2 Maintenance · Stable
|
57 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 2 Maintenance · Improved
|
43 Participants
|
74 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 2 Maintenance · Worsened
|
52 Participants
|
129 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 2 Maintenance · Stable
|
106 Participants
|
186 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 2 Maintenance · Improved
|
70 Participants
|
115 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 2 Maintenance · Worsened
|
54 Participants
|
115 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 2 Maintenance · Stable
|
125 Participants
|
229 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 2 Maintenance · Improved
|
49 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 2 Maintenance · Worsened
|
48 Participants
|
85 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 2 Maintenance · Stable
|
57 Participants
|
100 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 2 Maintenance · Improved
|
119 Participants
|
243 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 3 Maintenance · Worsened
|
70 Participants
|
159 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 3 Maintenance · Stable
|
88 Participants
|
147 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 3 Maintenance · Improved
|
74 Participants
|
135 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 3 Maintenance · Worsened
|
24 Participants
|
55 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 3 Maintenance · Stable
|
161 Participants
|
291 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 3 Maintenance · Improved
|
41 Participants
|
78 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 3 Maintenance · Worsened
|
71 Participants
|
161 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 3 Maintenance · Stable
|
55 Participants
|
109 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 3 Maintenance · Improved
|
106 Participants
|
171 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 3 Maintenance · Worsened
|
38 Participants
|
56 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 3 Maintenance · Stable
|
123 Participants
|
246 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 3 Maintenance · Improved
|
72 Participants
|
140 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 3 Maintenance · Worsened
|
129 Participants
|
285 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 3 Maintenance · Stable
|
53 Participants
|
91 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 3 Maintenance · Improved
|
50 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 3 Maintenance · Worsened
|
69 Participants
|
144 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 3 Maintenance · Stable
|
92 Participants
|
193 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 3 Maintenance · Improved
|
71 Participants
|
105 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 3 Maintenance · Worsened
|
54 Participants
|
110 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 3 Maintenance · Stable
|
118 Participants
|
242 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 3 Maintenance · Improved
|
60 Participants
|
90 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 3 Maintenance · Worsened
|
32 Participants
|
54 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 3 Maintenance · Stable
|
66 Participants
|
96 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 3 Maintenance · Improved
|
134 Participants
|
290 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Maintenance · Worsened
|
54 Participants
|
126 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Maintenance · Stable
|
72 Participants
|
132 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 6 Maintenance · Improved
|
69 Participants
|
139 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Maintenance · Worsened
|
16 Participants
|
45 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Maintenance · Stable
|
121 Participants
|
242 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 6 Maintenance · Improved
|
53 Participants
|
95 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Maintenance9 · Worsened
|
54 Participants
|
117 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Maintenance9 · Stable
|
44 Participants
|
101 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 6 Maintenance9 · Improved
|
97 Participants
|
179 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Maintenance · Worsened
|
22 Participants
|
49 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Maintenance · Stable
|
106 Participants
|
222 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 6 Maintenance · Improved
|
70 Participants
|
128 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Maintenance · Worsened
|
108 Participants
|
234 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Maintenance · Stable
|
43 Participants
|
89 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 6 Maintenance · Improved
|
47 Participants
|
75 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Maintenance · Worsened
|
53 Participants
|
127 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Maintenance · Stable
|
85 Participants
|
164 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 6 Maintenance · Improved
|
60 Participants
|
107 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Maintenance · Worsened
|
37 Participants
|
102 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Maintenance · Stable
|
111 Participants
|
200 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 6 Maintenance · Improved
|
50 Participants
|
96 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Maintenance · Worsened
|
13 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Maintenance · Stable
|
58 Participants
|
92 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 6 Maintenance · Improved
|
125 Participants
|
282 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 9 Maintenance · Worsened
|
51 Participants
|
99 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 9 Maintenance · Stable
|
59 Participants
|
130 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 9 Maintenance · Improved
|
75 Participants
|
130 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 9 Maintenance · Worsened
|
19 Participants
|
40 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 9 Maintenance · Stable
|
109 Participants
|
201 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 9 Maintenance · Improved
|
51 Participants
|
103 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 9 Maintenance · Worsened
|
47 Participants
|
89 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 9 Maintenance · Stable
|
39 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 9 Maintenance · Improved
|
99 Participants
|
184 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 9 Maintenance · Worsened
|
22 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 9 Maintenance · Stable
|
103 Participants
|
198 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 9 Maintenance · Improved
|
61 Participants
|
125 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 9 Maintenance · Worsened
|
91 Participants
|
206 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 9 Maintenance · Stable
|
52 Participants
|
75 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 9 Maintenance · Improved
|
43 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 9 Maintenance · Worsened
|
51 Participants
|
96 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 9 Maintenance · Stable
|
67 Participants
|
158 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 9 Maintenance · Improved
|
68 Participants
|
106 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 9 Maintenance · Worsened
|
39 Participants
|
81 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 9 Maintenance · Stable
|
101 Participants
|
193 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 9 Maintenance · Improved
|
46 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 9 Maintenance · Worsened
|
7 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 9 Maintenance · Stable
|
52 Participants
|
74 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 9 Maintenance · Improved
|
126 Participants
|
268 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 12 Maintenance · Worsened
|
32 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 12 Maintenance · Stable
|
57 Participants
|
99 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 12 Maintenance · Improved
|
67 Participants
|
130 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 12 Maintenance · Worsened
|
14 Participants
|
30 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 12 Maintenance · Stable
|
86 Participants
|
178 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 12 Maintenance · Improved
|
51 Participants
|
85 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 12 Maintenance · Worsened
|
35 Participants
|
83 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 12 Maintenance · Stable
|
39 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 12 Maintenance · Improved
|
82 Participants
|
166 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 12 Maintenance · Worsened
|
16 Participants
|
49 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 12 Maintenance · Stable
|
90 Participants
|
166 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 12 Maintenance · Improved
|
52 Participants
|
93 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 12 Maintenance · Worsened
|
68 Participants
|
164 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 12 Maintenance · Stable
|
46 Participants
|
73 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 12 Maintenance · Improved
|
44 Participants
|
71 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 12 Maintenance · Worsened
|
44 Participants
|
91 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 12 Maintenance · Stable
|
59 Participants
|
138 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 12 Maintenance · Improved
|
55 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 12 Maintenance · Worsened
|
25 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 12 Maintenance · Stable
|
95 Participants
|
164 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 12 Maintenance · Improved
|
38 Participants
|
78 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 12 Maintenance · Worsened
|
5 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 12 Maintenance · Stable
|
44 Participants
|
68 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 12 Maintenance · Improved
|
108 Participants
|
231 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 15 Maintenance · Worsened
|
40 Participants
|
73 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 15 Maintenance · Stable
|
54 Participants
|
92 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 15 Maintenance · Improved
|
55 Participants
|
114 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 15 Maintenance · Worsened
|
18 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 15 Maintenance · Stable
|
82 Participants
|
162 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 15 Maintenance · Improved
|
44 Participants
|
68 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 15 Maintenance · Worsened
|
26 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 15 Maintenance · Stable
|
35 Participants
|
69 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 15 Maintenance · Improved
|
88 Participants
|
151 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 15 Maintenance · Worsened
|
22 Participants
|
30 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 15 Maintenance · Stable
|
86 Participants
|
154 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 15 Maintenance · Improved
|
42 Participants
|
97 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 15 Maintenance · Worsened
|
66 Participants
|
147 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 15 Maintenance · Stable
|
42 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 15 Maintenance · Improved
|
42 Participants
|
72 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 15 Maintenance · Worsened
|
41 Participants
|
80 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 15 Maintenance · Stable
|
62 Participants
|
116 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 15 Maintenance · Improved
|
47 Participants
|
83 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 15 Maintenance · Worsened
|
30 Participants
|
60 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 15 Maintenance · Stable
|
80 Participants
|
144 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 15 Maintenance · Improved
|
40 Participants
|
74 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 15 Maintenance · Worsened
|
7 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 15 Maintenance · Improved
|
100 Participants
|
213 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 17 Maintenance · Worsened
|
10 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 17 Maintenance · Stable
|
13 Participants
|
32 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 17 Maintenance · Improved
|
16 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 17 Maintenance · Worsened
|
4 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 17 Maintenance · Improved
|
16 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 17 Maintenance · Worsened
|
8 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 17 Maintenance · Stable
|
6 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 17 Maintenance · Improved
|
25 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 17 Maintenance · Worsened
|
7 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 17 Maintenance · Stable
|
7 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 17 Maintenance · Improved
|
14 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 17 Maintenance · Worsened
|
10 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 17 Maintenance · Stable
|
11 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 17 Maintenance · Improved
|
19 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 17 Maintenance · Worsened
|
7 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 17 Maintenance · Stable
|
20 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 17 Maintenance · Improved
|
13 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 17 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 17 Maintenance · Stable
|
10 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 17 Maintenance · Improved
|
28 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 23 Maintenance · Worsened
|
9 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 23 Maintenance · Stable
|
20 Participants
|
37 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 23 Maintenance · Improved
|
26 Participants
|
37 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 23 Maintenance · Worsened
|
4 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 23 Maintenance · Stable
|
36 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 23 Maintenance · Improved
|
14 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 23 Maintenance · Worsened
|
8 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 23 Maintenance · Stable
|
15 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, End of treatment · Worsened
|
42 Participants
|
97 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 23 Maintenance · Improved
|
32 Participants
|
57 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 23 Maintenance · Worsened
|
8 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 23 Maintenance · Stable
|
34 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 23 Maintenance · Improved
|
14 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 23 Maintenance · Worsened
|
20 Participants
|
50 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 23 Maintenance · Stable
|
18 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 23 Maintenance · Improved
|
18 Participants
|
32 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 23 Maintenance · Worsened
|
18 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 23 Maintenance · Stable
|
25 Participants
|
46 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 23 Maintenance · Improved
|
13 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 23 Maintenance · Worsened
|
9 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 23 Maintenance · Stable
|
28 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 23 Maintenance · Improved
|
19 Participants
|
30 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 23 Maintenance · Worsened
|
4 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 23 Maintenance · Stable
|
17 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 23 Maintenance · Improved
|
35 Participants
|
74 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 29 Maintenance · Worsened
|
13 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 29 Maintenance · Stable
|
18 Participants
|
29 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 29 Maintenance · Improved
|
20 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 29 Maintenance · Worsened
|
5 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 29 Maintenance · Stable
|
25 Participants
|
46 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 29 Maintenance · Improved
|
19 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 29 Maintenance · Worsened
|
8 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 29 Maintenance · Stable
|
11 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 29 Maintenance · Improved
|
32 Participants
|
55 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 29 Maintenance · Worsened
|
9 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 29 Maintenance · Stable
|
30 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 29 Maintenance · Improved
|
12 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 29 Maintenance · Worsened
|
17 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 29 Maintenance · Stable
|
16 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 29 Maintenance · Improved
|
17 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 29 Maintenance · Worsened
|
14 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 29 Maintenance · Stable
|
16 Participants
|
45 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 29 Maintenance · Improved
|
20 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 29 Maintenance · Worsened
|
7 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 29 Maintenance · Improved
|
13 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 29 Maintenance · Worsened
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 29 Maintenance · Stable
|
14 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 29 Maintenance · Improved
|
35 Participants
|
68 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 35 Maintenance · Worsened
|
13 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 35 Maintenance · Stable
|
11 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 35 Maintenance · Improved
|
21 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 35 Maintenance · Worsened
|
5 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 35 Maintenance · Stable
|
26 Participants
|
47 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 35 Maintenance · Improved
|
13 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 35 Maintenance · Worsened
|
9 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 35 Maintenance · Stable
|
11 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 35 Maintenance · Improved
|
25 Participants
|
50 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 35 Maintenance · Worsened
|
6 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 35 Maintenance · Stable
|
25 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 35 Maintenance · Improved
|
13 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 35 Maintenance · Worsened
|
14 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 35 Maintenance · Stable
|
19 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 35 Maintenance · Improved
|
12 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 35 Maintenance · Worsened
|
9 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 35 Maintenance · Stable
|
17 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 35 Maintenance · Improved
|
19 Participants
|
22 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 35 Maintenance · Worsened
|
10 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 35 Maintenance · Stable
|
24 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 35 Maintenance · Improved
|
11 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 35 Maintenance · Worsened
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 35 Maintenance · Stable
|
15 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 35 Maintenance · Improved
|
28 Participants
|
64 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 41 Maintenance · Worsened
|
23 Participants
|
30 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 41 Maintenance · Stable
|
15 Participants
|
36 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 41 Maintenance · Improved
|
19 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 41 Maintenance · Worsened
|
6 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 41 Maintenance · Stable
|
30 Participants
|
53 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 41 Maintenance · Improved
|
21 Participants
|
34 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 41 Maintenance · Worsened
|
10 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 41 Maintenance · Stable
|
13 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 41 Maintenance · Improved
|
34 Participants
|
57 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 41 Maintenance · Worsened
|
11 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 41 Maintenance · Stable
|
31 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 41 Maintenance · Improved
|
15 Participants
|
36 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 41 Maintenance · Worsened
|
25 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 41 Maintenance · Stable
|
19 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 41 Maintenance · Improved
|
12 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 41 Maintenance · Worsened
|
18 Participants
|
29 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 41 Maintenance · Stable
|
19 Participants
|
51 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 41 Maintenance · Improved
|
19 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 41 Maintenance · Worsened
|
15 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 41 Maintenance · Stable
|
26 Participants
|
50 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 41 Maintenance · Improved
|
15 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 41 Maintenance · Worsened
|
3 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 41 Maintenance · Stable
|
17 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 41 Maintenance · Improved
|
37 Participants
|
77 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 47 Maintenance · Worsened
|
14 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 47 Maintenance · Worsened
|
6 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 47 Maintenance · Stable
|
21 Participants
|
46 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 47 Maintenance · Improved
|
20 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 47 Maintenance · Worsened
|
7 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 47 Maintenance · Stable
|
9 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 47 Maintenance · Improved
|
31 Participants
|
47 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 47 Maintenance · Worsened
|
10 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 47 Maintenance · Stable
|
28 Participants
|
44 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 47 Maintenance · Improved
|
9 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 47 Maintenance · Worsened
|
21 Participants
|
40 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 47 Maintenance · Stable
|
14 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 47 Maintenance · Improved
|
12 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 47 Maintenance · Worsened
|
12 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 47 Maintenance · Stable
|
19 Participants
|
43 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 47 Maintenance · Improved
|
16 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 47 Maintenance · Worsened
|
9 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 47 Maintenance · Stable
|
29 Participants
|
44 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 47 Maintenance · Improved
|
9 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 47 Maintenance · Worsened
|
5 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 47 Maintenance · Stable
|
12 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 47 Maintenance · Improved
|
30 Participants
|
60 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 53 Maintenance · Worsened
|
10 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 53 Maintenance · Stable
|
8 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 53 Maintenance · Improved
|
8 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 53 Maintenance · Worsened
|
4 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 53 Maintenance · Stable
|
11 Participants
|
32 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 53 Maintenance · Improved
|
11 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 53 Maintenance · Worsened
|
3 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 53 Maintenance · Stable
|
5 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 53 Maintenance · Improved
|
18 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 53 Maintenance · Worsened
|
5 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 53 Maintenance · Stable
|
15 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 53 Maintenance · Improved
|
6 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 53 Maintenance · Worsened
|
7 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 53 Maintenance · Stable
|
13 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 53 Maintenance · Improved
|
6 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 53 Maintenance · Worsened
|
7 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 53 Maintenance · Stable
|
9 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 53 Maintenance · Improved
|
10 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 53 Maintenance · Worsened
|
4 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 53 Maintenance · Stable
|
14 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 53 Maintenance · Improved
|
8 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 53 Maintenance · Worsened
|
4 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 53 Maintenance · Stable
|
8 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 53 Maintenance · Improved
|
14 Participants
|
41 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 59 Maintenance · Worsened
|
6 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 59 Maintenance · Stable
|
6 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 59 Maintenance · Improved
|
6 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 59 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 59 Maintenance · Stable
|
9 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 59 Maintenance · Improved
|
8 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 59 Maintenance · Worsened
|
3 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 59 Maintenance · Stable
|
5 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 59 Maintenance · Improved
|
10 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 59 Maintenance · Worsened
|
3 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 59 Maintenance · Stable
|
12 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 59 Maintenance · Improved
|
3 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 59 Maintenance · Worsened
|
7 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 59 Maintenance · Stable
|
6 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 59 Maintenance · Improved
|
5 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 59 Maintenance · Worsened
|
5 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 59 Maintenance · Stable
|
6 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 59 Maintenance · Improved
|
7 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 59 Maintenance · Worsened
|
3 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 59 Maintenance · Stable
|
10 Participants
|
22 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 59 Maintenance · Improved
|
5 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 59 Maintenance · Worsened
|
4 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 59 Maintenance · Stable
|
4 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 59 Maintenance · Improved
|
10 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 65 Maintenance · Worsened
|
3 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 65 Maintenance · Stable
|
4 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 65 Maintenance · Improved
|
5 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 65 Maintenance · Worsened
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 65 Maintenance · Stable
|
5 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 65 Maintenance · Improved
|
5 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 65 Maintenance · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 65 Maintenance · Stable
|
5 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 65 Maintenance · Improved
|
6 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 65 Maintenance · Worsened
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 65 Maintenance · Stable
|
9 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 65 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 65 Maintenance · Worsened
|
5 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 65 Maintenance · Stable
|
5 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 65 Maintenance · Improved
|
2 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 65 Maintenance · Worsened
|
3 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 65 Maintenance · Stable
|
3 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 65 Maintenance · Improved
|
6 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 65 Maintenance · Worsened
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 65 Maintenance · Stable
|
9 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 65 Maintenance · Improved
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 65 Maintenance · Worsened
|
4 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 65 Maintenance · Stable
|
4 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 65 Maintenance · Improved
|
4 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 71 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 71 Maintenance · Stable
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 71 Maintenance · Improved
|
6 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 71 Maintenance · Worsened
|
2 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 71 Maintenance · Stable
|
4 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 71 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 71 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 71 Maintenance · Stable
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 71 Maintenance · Improved
|
6 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 71 Maintenance · Worsened
|
3 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 71 Maintenance · Stable
|
4 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 71 Maintenance · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 71 Maintenance · Worsened
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 71 Maintenance · Stable
|
4 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 71 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 71 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 71 Maintenance · Stable
|
1 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 71 Maintenance · Improved
|
5 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 71 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 71 Maintenance · Stable
|
5 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 71 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 71 Maintenance · Worsened
|
3 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 71 Maintenance · Stable
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 71 Maintenance · Improved
|
3 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 77 Maintenance · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 77 Maintenance · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 77 Maintenance · Improved
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 77 Maintenance · Worsened
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 77 Maintenance · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 77 Maintenance · Improved
|
0 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 77 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 77 Maintenance · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 77 Maintenance · Improved
|
3 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 77 Maintenance · Worsened
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 77 Maintenance · Stable
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 77 Maintenance · Improved
|
2 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 77 Maintenance · Worsened
|
2 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 77 Maintenance · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 77 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 77 Maintenance · Worsened
|
0 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 77 Maintenance · Stable
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 77 Maintenance · Improved
|
4 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 77 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 77 Maintenance · Stable
|
2 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 77 Maintenance · Improved
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 77 Maintenance · Worsened
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 77 Maintenance · Stable
|
2 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 77 Maintenance · Improved
|
2 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 83 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 83 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 83 Maintenance · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 83 Maintenance · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 83 Maintenance · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 83 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 83 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 83 Maintenance · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 83 Maintenance · Improved
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 83 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 83 Maintenance · Stable
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 83 Maintenance · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 83 Maintenance · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 83 Maintenance · Improved
|
2 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 83 Maintenance · Stable
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 83 Maintenance · Improved
|
3 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 83 Maintenance · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 83 Maintenance · Stable
|
1 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 83 Maintenance · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 83 Maintenance · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 83 Maintenance · Stable
|
2 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 83 Maintenance · Improved
|
1 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 89 Maintenance · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Cycle 89 Maintenance · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 89 Maintenance · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Cycle 89 Maintenance · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 89 Maintenance · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 89 Maintenance · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Cycle 89 Maintenance · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, End of treatment · Worsened
|
45 Participants
|
94 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, End of treatment · Stable
|
68 Participants
|
109 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, End of treatment · Improved
|
68 Participants
|
134 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, End of treatment · Worsened
|
21 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, End of treatment · Stable
|
122 Participants
|
206 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, End of treatment · Improved
|
33 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, End of treatment · Worsened
|
65 Participants
|
124 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, End of treatment · Stable
|
43 Participants
|
72 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, End of treatment · Improved
|
72 Participants
|
142 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, End of treatment · Worsened
|
45 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, End of treatment · Stable
|
90 Participants
|
186 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, End of treatment · Improved
|
46 Participants
|
96 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, End of treatment · Worsened
|
79 Participants
|
171 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, End of treatment · Stable
|
52 Participants
|
83 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, End of treatment · Improved
|
50 Participants
|
85 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 63 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, End of treatment · Stable
|
83 Participants
|
149 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, End of treatment · Improved
|
56 Participants
|
94 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, End of treatment · Worsened
|
35 Participants
|
75 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, End of treatment · Stable
|
94 Participants
|
180 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, End of treatment · Improved
|
52 Participants
|
85 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, End of treatment · Worsened
|
13 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, End of treatment · Stable
|
45 Participants
|
76 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, End of treatment · Improved
|
122 Participants
|
240 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Safety Follow-up · Worsened
|
42 Participants
|
94 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Safety Follow-up · Stable
|
47 Participants
|
84 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, Safety Follow-up · Improved
|
52 Participants
|
102 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Safety Follow-up · Worsened
|
16 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Safety Follow-up · Stable
|
90 Participants
|
175 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, Safety Follow-up · Improved
|
28 Participants
|
55 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Safety Follow-up · Worsened
|
50 Participants
|
111 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Safety Follow-up · Stable
|
32 Participants
|
67 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, Safety Follow-up · Improved
|
59 Participants
|
103 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Safety Follow-up · Worsened
|
22 Participants
|
55 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Safety Follow-up · Stable
|
78 Participants
|
152 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, Safety Follow-up · Improved
|
43 Participants
|
75 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Safety Follow-up · Worsened
|
72 Participants
|
151 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Safety Follow-up · Stable
|
36 Participants
|
70 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, Safety Follow-up · Improved
|
35 Participants
|
61 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Safety Follow-up · Worsened
|
29 Participants
|
83 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Safety Follow-up · Stable
|
67 Participants
|
130 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, Safety Follow-up · Improved
|
47 Participants
|
69 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Safety Follow-up · Worsened
|
29 Participants
|
66 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Safety Follow-up · Stable
|
77 Participants
|
139 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, Safety Follow-up · Improved
|
37 Participants
|
77 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Safety Follow-up · Worsened
|
15 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Safety Follow-up · Stable
|
37 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, Safety Follow-up · Improved
|
90 Participants
|
203 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 3 months) · Worsened
|
47 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 3 months) · Stable
|
46 Participants
|
83 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 3 months) · Improved
|
41 Participants
|
81 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 3 months) · Worsened
|
24 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 3 months) · Stable
|
79 Participants
|
157 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 3 months) · Improved
|
25 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 3 months) · Worsened
|
46 Participants
|
88 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 3 months) · Stable
|
33 Participants
|
47 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 3 months) · Improved
|
55 Participants
|
108 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 3 months) · Worsened
|
23 Participants
|
44 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 3 months) · Stable
|
68 Participants
|
132 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 3 months) · Improved
|
43 Participants
|
67 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 3 months) · Worsened
|
63 Participants
|
135 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 3 months) · Stable
|
39 Participants
|
56 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 3 months) · Improved
|
32 Participants
|
52 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 3 months) · Worsened
|
27 Participants
|
56 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 3 months) · Stable
|
52 Participants
|
108 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 3 months) · Improved
|
55 Participants
|
78 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 3 months) · Worsened
|
30 Participants
|
67 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 3 months) · Stable
|
79 Participants
|
116 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 3 months) · Improved
|
25 Participants
|
60 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 3 months) · Worsened
|
17 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 3 months) · Stable
|
29 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 3 months) · Improved
|
86 Participants
|
173 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 9 months) · Worsened
|
36 Participants
|
56 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 9 months) · Stable
|
37 Participants
|
56 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 9 months) · Improved
|
34 Participants
|
68 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 9 months) · Worsened
|
13 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 9 months) · Stable
|
74 Participants
|
110 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 9 months) · Improved
|
19 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 9 months) · Worsened
|
42 Participants
|
67 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 9 months) · Stable
|
17 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 9 months) · Improved
|
47 Participants
|
84 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 9 months) · Worsened
|
18 Participants
|
35 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 9 months) · Stable
|
58 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 9 months) · Improved
|
31 Participants
|
59 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 9 months) · Worsened
|
60 Participants
|
92 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 9 months) · Stable
|
24 Participants
|
47 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 9 months) · Improved
|
23 Participants
|
41 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 9 months) · Worsened
|
22 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 9 months) · Stable
|
50 Participants
|
82 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 9 months) · Improved
|
35 Participants
|
60 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 9 months) · Worsened
|
32 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 9 months) · Stable
|
54 Participants
|
88 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 9 months) · Improved
|
21 Participants
|
44 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 9 months) · Worsened
|
12 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 9 months) · Stable
|
26 Participants
|
40 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 9 months) · Improved
|
69 Participants
|
123 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 15 months) · Worsened
|
22 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 15 months) · Stable
|
31 Participants
|
46 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 15 months) · Improved
|
23 Participants
|
61 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 15 months) · Worsened
|
12 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 15 months) · Stable
|
43 Participants
|
86 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 15 months) · Improved
|
15 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 15 months) · Worsened
|
30 Participants
|
54 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 15 months) · Stable
|
16 Participants
|
33 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 15 months) · Improved
|
30 Participants
|
61 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 15 months) · Worsened
|
19 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 15 months) · Stable
|
37 Participants
|
81 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 15 months) · Improved
|
20 Participants
|
45 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 15 months) · Worsened
|
43 Participants
|
79 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 15 months) · Stable
|
13 Participants
|
40 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 15 months) · Improved
|
20 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 15 months) · Worsened
|
17 Participants
|
37 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 15 months) · Stable
|
41 Participants
|
78 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 15 months) · Improved
|
18 Participants
|
34 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 15 months) · Worsened
|
19 Participants
|
45 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 15 months) · Stable
|
41 Participants
|
73 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 15 months) · Improved
|
16 Participants
|
29 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 15 months) · Worsened
|
7 Participants
|
13 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 15 months) · Stable
|
21 Participants
|
34 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 15 months) · Improved
|
48 Participants
|
101 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 21 months) · Worsened
|
12 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 21 months) · Stable
|
18 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 21 months) · Improved
|
16 Participants
|
39 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 21 months) · Worsened
|
5 Participants
|
13 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 21 months) · Stable
|
26 Participants
|
62 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 21 months) · Improved
|
13 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 21 months) · Worsened
|
17 Participants
|
36 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 21 months) · Stable
|
11 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 21 months) · Improved
|
18 Participants
|
42 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 21 months) · Worsened
|
12 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 21 months) · Stable
|
25 Participants
|
48 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 21 months) · Improved
|
10 Participants
|
29 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 21 months) · Worsened
|
18 Participants
|
53 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 21 months) · Stable
|
13 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 21 months) · Improved
|
15 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 21 months) · Worsened
|
12 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 21 months) · Stable
|
21 Participants
|
44 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 21 months) · Improved
|
14 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 21 months) · Worsened
|
10 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 21 months) · Stable
|
27 Participants
|
50 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 21 months) · Improved
|
9 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 21 months) · Worsened
|
4 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 21 months) · Stable
|
6 Participants
|
22 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 21 months) · Improved
|
37 Participants
|
62 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 27 months) · Worsened
|
10 Participants
|
21 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 27 months) · Stable
|
15 Participants
|
22 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 63 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 63 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 63 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 63 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 63 months) · Stable
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 63 months) · Improved
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 27 months) · Improved
|
10 Participants
|
26 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 27 months) · Worsened
|
6 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 27 months) · Stable
|
18 Participants
|
41 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 27 months) · Improved
|
8 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 27 months) · Worsened
|
16 Participants
|
28 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 27 months) · Stable
|
7 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 27 months) · Improved
|
11 Participants
|
27 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 27 months) · Worsened
|
5 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 27 months) · Stable
|
21 Participants
|
38 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 27 months) · Improved
|
9 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 27 months) · Worsened
|
19 Participants
|
36 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 27 months) · Stable
|
9 Participants
|
16 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 27 months) · Improved
|
7 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 27 months) · Worsened
|
8 Participants
|
17 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 27 months) · Stable
|
18 Participants
|
29 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 27 months) · Improved
|
9 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 27 months) · Worsened
|
11 Participants
|
24 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 27 months) · Stable
|
18 Participants
|
31 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 27 months) · Improved
|
6 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 27 months) · Worsened
|
6 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 27 months) · Stable
|
7 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 27 months) · Improved
|
22 Participants
|
47 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 33 months) · Worsened
|
1 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 33 months) · Stable
|
8 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 33 months) · Improved
|
7 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 33 months) · Worsened
|
0 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 33 months) · Stable
|
13 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 33 months) · Improved
|
3 Participants
|
9 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 33 months) · Worsened
|
9 Participants
|
15 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 33 months) · Stable
|
4 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 33 months) · Improved
|
3 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 33 months) · Worsened
|
4 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 33 months) · Stable
|
7 Participants
|
25 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 33 months) · Improved
|
5 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 33 months) · Worsened
|
8 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 33 months) · Stable
|
5 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 33 months) · Improved
|
2 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 33 months) · Worsened
|
2 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 33 months) · Worsened
|
4 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 33 months) · Stable
|
7 Participants
|
20 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 33 months) · Improved
|
4 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 33 months) · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 33 months) · Stable
|
3 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 33 months) · Improved
|
11 Participants
|
23 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 39 months) · Stable
|
6 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 39 months) · Improved
|
2 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 39 months) · Worsened
|
0 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 39 months) · Stable
|
10 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 39 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 39 months) · Improved
|
5 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 39 months) · Worsened
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 39 months) · Stable
|
6 Participants
|
18 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 39 months) · Improved
|
3 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 39 months) · Worsened
|
5 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 39 months) · Stable
|
4 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 39 months) · Improved
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 39 months) · Worsened
|
4 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 39 months) · Stable
|
6 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 39 months) · Improved
|
1 Participants
|
7 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 39 months) · Worsened
|
3 Participants
|
8 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 39 months) · Stable
|
7 Participants
|
14 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 39 months) · Improved
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 39 months) · Worsened
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 39 months) · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 39 months) · Improved
|
7 Participants
|
19 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 45 months) · Stable
|
3 Participants
|
11 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 45 months) · Improved
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 45 months) · Worsened
|
3 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 45 months) · Stable
|
0 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 45 months) · Stable
|
2 Participants
|
10 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 45 months) · Improved
|
2 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 45 months) · Stable
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
6 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 45 months) · Stable
|
3 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 45 months) · Worsened
|
1 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 45 months) · Worsened
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 45 months) · Stable
|
3 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 45 months) · Improved
|
1 Participants
|
12 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 51 months) · Worsened
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 51 months) · Stable
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 51 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 51 months) · Stable
|
0 Participants
|
4 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 51 months) · Worsened
|
2 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 51 months) · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
ATD, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 51 months) · Stable
|
2 Participants
|
5 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
AS, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 51 months) · Worsened
|
2 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 51 months) · Stable
|
0 Participants
|
2 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
PN, LTFU (EOT + 51 months) · Improved
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 51 months) · Improved
|
1 Participants
|
3 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 57 months) · Stable
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
BI, LTFU (EOT + 57 months) · Improved
|
1 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 57 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 57 months) · Stable
|
0 Participants
|
1 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
S, LTFU (EOT + 57 months) · Improved
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
MS, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
CSE, LTFU (EOT + 57 months) · Worsened
|
1 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 57 months) · Worsened
|
0 Participants
|
0 Participants
|
|
Number of Participants With Change in Status in EORTC-QLQ Ovarian Cancer Module (EORTC-QLQ-OV28) Questionnaire
HS, LTFU (EOT + 57 months) · Stable
|
0 Participants
|
1 Participants
|
Adverse Events
Not Treated
Serious events: 35 serious events
Other events: 51 other events
Deaths: 33 deaths
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)
Serious events: 63 serious events
Other events: 158 other events
Deaths: 106 deaths
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
Serious events: 190 serious events
Other events: 417 other events
Deaths: 235 deaths
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
Serious events: 405 serious events
Other events: 745 other events
Deaths: 430 deaths
Serious adverse events
| Measure |
Not Treated
n=79 participants at risk
Eligible participants with ovarian cancer received standard of care (SOC) chemotherapy as combination of 175 milligram (mg)/meter\^2(m\^2) Paclitaxel, area under the curve (AUC) of 5 to 6 mg/millilitre (mL)/minute Carboplatin and optional 7.5 mg/kilogram (kg) or 15 mg/kg Bevacizumab as intravenous (IV) infusion on Day 1 of Cycle 1 in Chemotherapy Run-In Period. They were not randomized to chemotherapy treatment period and no study intervention was administered.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)
n=159 participants at risk
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo (Pbo) on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles starting with Cycle 2, with optional Bevacizumab (Bev) as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib placebo Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=417 participants at risk
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=745 participants at risk
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
6/159 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.4%
10/417 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.4%
25/745 • Number of events 28 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Small intestinal obstruction
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.9%
12/417 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.8%
21/745 • Number of events 25 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Intestinal obstruction
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.6%
11/417 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.3%
17/745 • Number of events 20 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Vomiting
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
9/745 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Diarrhoea
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
5/417 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.1%
8/745 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.1%
8/745 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Nausea
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.67%
5/745 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Ileus
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Subileus
|
2.5%
2/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Large intestine perforation
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Ascites
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Enterocolitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Intestinal perforation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Large intestinal obstruction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Rectal haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Anal fistula
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Colonic fistula
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Diarrhoea haemorrhagic
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastrointestinal toxicity
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Haematemesis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Intestinal ischaemia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Pancreatitis acute
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Small intestinal perforation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Stomatitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Diaphragmatic hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Duodenal obstruction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Enteritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastric haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastric ulcer haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastrointestinal fistula
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastrointestinal obstruction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Hernial eventration
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Ileus paralytic
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Immune-mediated enterocolitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Immune-mediated gastritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Impaired gastric emptying
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Incarcerated inguinal hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Incarcerated umbilical hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Intestinal prolapse
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Intra-abdominal haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Irritable bowel syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Melaena
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Neutropenic colitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Oesophagitis ulcerative
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Rectal perforation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Retroperitoneal haematoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Umbilical hernia, obstructive
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Vasculitis gastrointestinal
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Volvulus
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Volvulus of small bowel
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
COVID-19
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.7%
7/417 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.5%
11/745 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Sepsis
|
2.5%
2/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.5%
11/745 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.6%
12/745 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pneumonia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.4%
6/417 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
9/745 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Abdominal abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.67%
5/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pyelonephritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Septic shock
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Device related infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Neutropenic sepsis
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Urosepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Vascular device infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
COVID-19 pneumonia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Clostridium difficile infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Device related sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Enterocolitis infectious
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Escherichia sepsis
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pelvic abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Peritonitis
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pneumocystis jirovecii pneumonia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Suspected COVID-19
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Wound infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Abdominal infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Cellulitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Clostridial sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Clostridium difficile colitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Device related bacteraemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Enterobacter sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Klebsiella sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Post procedural infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Splenic abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Staphylococcal infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Appendiceal abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Appendicitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Appendicitis perforated
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Arthritis bacterial
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Atypical pneumonia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Bacteraemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Bacterial sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Bronchitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Clostridial infection
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Coronavirus infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Diverticulitis intestinal perforated
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Encephalitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Endocarditis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Escherichia infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Gastroenteritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Gastroenteritis shigella
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Gastrointestinal infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Haemophilus infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Hepatitis A
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Herpes zoster
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Infected lymphocele
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Infected seroma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Infective exacerbation of chronic obstructive airways disease
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Large intestine infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Legionella infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Listeria sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Meningitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Meningoencephalitis viral
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Nasal abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Neutropenic infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Perirectal abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pharyngitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Post procedural cellulitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Post procedural sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pseudomonas infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Pulmonary sepsis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Respiratory syncytial virus infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Skin infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Soft tissue infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Stoma site infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Streptococcal infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Subdiaphragmatic abscess
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Tooth infection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Urinary tract infection pseudomonal
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Vulvitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Wound infection staphylococcal
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.0%
25/417 • Number of events 27 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.2%
31/745 • Number of events 35 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.6%
19/417 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
28/745 • Number of events 30 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Febrile neutropenia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.4%
6/417 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.7%
20/745 • Number of events 20 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
8/417 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.94%
7/745 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Pancytopenia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.4%
6/417 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Febrile bone marrow aplasia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Aplasia pure red cell
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Acquired amegakaryocytic thrombocytopenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Atypical haemolytic uraemic syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Cytopenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Haematotoxicity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Haemolytic anaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Splenic haematoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Thrombotic microangiopathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.7%
7/417 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.7%
13/745 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pleural effusion
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
2/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.7%
7/417 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
10/745 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.3%
10/745 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pneumonitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.1%
8/745 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Lung disorder
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Interstitial lung disease
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary mass
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Dysphonia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Haemothorax
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Malignant pleural effusion
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pleurisy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary amyloidosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory failure
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Pyrexia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.8%
21/745 • Number of events 23 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Asthenia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.94%
7/745 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
General physical health deterioration
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Mucosal inflammation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Chest pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Fatigue
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Hyperthermia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Inflammation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Malaise
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Chest discomfort
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Hernia obstructive
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Impaired healing
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Multiple organ dysfunction syndrome
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Non-cardiac chest pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Oedema peripheral
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Performance status decreased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Sudden cardiac death
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Sudden death
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Platelet count decreased
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.4%
10/417 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
28/745 • Number of events 30 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.1%
8/745 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Neutrophil count decreased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.67%
5/745 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Aspartate aminotransferase increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood creatinine increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
SARS-CoV-2 test positive
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Transaminases increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood alkaline phosphatase increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
White blood cell count decreased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood thyroid stimulating hormone increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
General physical condition abnormal
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Haemoglobin decreased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Hepatic enzyme abnormal
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Hepatic enzyme increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Dehydration
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.4%
6/417 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
9/745 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
5/417 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Failure to thrive
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Acidosis
|
1.3%
1/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Calciphylaxis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypertriglyceridaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypocalcaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Ketoacidosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Type 1 diabetes mellitus
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Hip fracture
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Postoperative ileus
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Wound dehiscence
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Abdominal wound dehiscence
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Gastrointestinal procedural complication
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Failure to anastomose
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Femoral neck fracture
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Eye disorders
Uveitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Gastrointestinal anastomotic leak
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Gastrointestinal stoma complication
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Iatrogenic injury
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Incarcerated incisional hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Incisional hernia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Joint dislocation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Post procedural complication
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Post procedural haematoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Postoperative respiratory failure
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Procedural complication
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Procedural haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Procedural intestinal perforation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Road traffic accident
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Spinal fracture
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Thoracic vertebral fracture
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Toxicity to various agents
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Upper limb fracture
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Vulvovaginal injury
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Cerebrovascular accident
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Syncope
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Transient ischaemic attack
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.67%
5/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Loss of consciousness
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Dizziness
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Encephalopathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Headache
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Neuropathy peripheral
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Sciatica
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Aphasia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Cognitive disorder
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Facial paralysis
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Myasthenic syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Optic neuritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Parkinsonism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Posterior reversible encephalopathy syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Transient aphasia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
VIth nerve paralysis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Embolism
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Hypertension
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.81%
6/745 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Deep vein thrombosis
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Hypotension
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Lymphocele
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Circulatory collapse
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Hypertensive urgency
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Jugular vein thrombosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Orthostatic hypotension
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Peripheral ischaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Vasculitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Atrial fibrillation
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Myocardial infarction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Supraventricular tachycardia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Acute coronary syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardiac arrest
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardiomyopathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Myocarditis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Sinus tachycardia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Acute cardiac event
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Acute left ventricular failure
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Acute myocardial infarction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Angina unstable
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Atrial thrombosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardiac failure
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardiac failure acute
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardiac failure congestive
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Cardio-respiratory arrest
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Coronary artery disease
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Immune-mediated myocarditis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Myocardial ischaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Pericarditis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Stress cardiomyopathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Ventricular extrasystoles
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Acute kidney injury
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
9/745 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Urinary retention
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Pyelocaliectasis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Tubulointerstitial nephritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Immune-mediated nephritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Nephritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Obstructive nephropathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Urinary bladder polyp
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Urogenital fistula
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Vesical fistula
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myeloid leukaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.54%
4/745 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast cancer
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Myelodysplastic syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute monocytic leukaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Acute myelomonocytic leukaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma of colon
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma pancreas
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal cell carcinoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Endometrial cancer
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Gallbladder adenocarcinoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung adenocarcinoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Ovarian Sertoli-Leydig cell tumour
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Plasma cell myeloma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Polycythaemia vera
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal cancer
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous cell carcinoma of skin
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Tumour associated fever
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Cholecystitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.40%
3/745 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Autoimmune hepatitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Cholangitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Hepatitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Bile duct stone
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Hepatobiliary disorders
Hypertransaminasaemia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Adrenal insufficiency
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.67%
5/745 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Hypophysitis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Autoimmune thyroiditis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Immune-mediated hypothyroidism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Primary hypothyroidism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Secondary adrenocortical insufficiency
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Flank pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal chest pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Degenerative bone disease
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Soft tissue necrosis
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Depression
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.48%
2/417 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Delirium
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Mental status changes
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Suicide attempt
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Confusional state
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Suicidal ideation
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Anaphylactic reaction
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Cytokine release syndrome
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.24%
1/417 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Sarcoidosis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Toxic skin eruption
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Dermatitis exfoliative generalised
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Reproductive system and breast disorders
Pelvic pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.72%
3/417 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Reproductive system and breast disorders
Pelvic fluid collection
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Reproductive system and breast disorders
Pelvic haematoma
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Reproductive system and breast disorders
Vaginal discharge
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Reproductive system and breast disorders
Vaginal haemorrhage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.63%
1/159 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/745 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Eye disorders
Retinal detachment
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.27%
2/745 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Eye disorders
Blindness
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Eye disorders
Vitreous floaters
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Ear and labyrinth disorders
Deafness
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Product Issues
Device breakage
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Surgical and medical procedures
Ileostomy closure
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/417 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.13%
1/745 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
Other adverse events
| Measure |
Not Treated
n=79 participants at risk
Eligible participants with ovarian cancer received standard of care (SOC) chemotherapy as combination of 175 milligram (mg)/meter\^2(m\^2) Paclitaxel, area under the curve (AUC) of 5 to 6 mg/millilitre (mL)/minute Carboplatin and optional 7.5 mg/kilogram (kg) or 15 mg/kg Bevacizumab as intravenous (IV) infusion on Day 1 of Cycle 1 in Chemotherapy Run-In Period. They were not randomized to chemotherapy treatment period and no study intervention was administered.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib Pbo+Dostarlimab Pbo +/-Bev (Arm1)
n=159 participants at risk
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo (Pbo) on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles starting with Cycle 2, with optional Bevacizumab (Bev) as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib placebo Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2)
n=417 participants at risk
Participants received intravenous (IV) infusion of Carboplatin+Paclitaxel along with Dostarlimab placebo on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab Placebo on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3)
n=745 participants at risk
Participants received intravenous (IV) infusion of Carboplatin + Paclitaxel along with Dostarlimab on Day 1 of each 21-day (Q21D) cycle for up to 5 cycles, starting with Cycle 2 with optional Bevacizumab as part of Chemotherapy. Following this, as part of Maintenance, participants received IV infusion of 1000 mg Dostarlimab on Day 1 every 6 weeks in combination with/without 7.5 mg/kg or 15 mg/kg Bevacizumab Q21D along with oral niraparib Q21D until disease progression, unacceptable toxicity, participant withdrawal, or Investigator decision.
|
|---|---|---|---|---|
|
Gastrointestinal disorders
Nausea
|
19.0%
15/79 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
54.1%
86/159 • Number of events 150 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
60.2%
251/417 • Number of events 485 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
59.5%
443/745 • Number of events 1010 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Constipation
|
8.9%
7/79 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
44.0%
70/159 • Number of events 106 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
46.3%
193/417 • Number of events 339 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
49.0%
365/745 • Number of events 617 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Diarrhoea
|
13.9%
11/79 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
39.6%
63/159 • Number of events 94 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
35.5%
148/417 • Number of events 282 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
39.7%
296/745 • Number of events 560 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal pain
|
10.1%
8/79 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
29.6%
47/159 • Number of events 64 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
28.5%
119/417 • Number of events 184 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
35.2%
262/745 • Number of events 410 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Vomiting
|
13.9%
11/79 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
21.4%
34/159 • Number of events 52 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
31.7%
132/417 • Number of events 197 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
32.2%
240/745 • Number of events 419 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Stomatitis
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.5%
12/159 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.5%
48/417 • Number of events 66 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.8%
103/745 • Number of events 167 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal pain upper
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
8/159 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.8%
45/417 • Number of events 57 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.6%
79/745 • Number of events 90 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.9%
11/159 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.9%
33/417 • Number of events 39 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.2%
76/745 • Number of events 97 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Dyspepsia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.5%
12/159 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.9%
37/417 • Number of events 44 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.1%
60/745 • Number of events 74 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Dry mouth
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.1%
5/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 27 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.5%
71/745 • Number of events 86 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Gastrooesophageal reflux disease
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.4%
15/159 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.8%
24/417 • Number of events 30 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.8%
51/745 • Number of events 54 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal pain lower
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 29 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.9%
29/745 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 25 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.4%
25/745 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Fatigue
|
7.6%
6/79 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
38.4%
61/159 • Number of events 98 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
36.2%
151/417 • Number of events 306 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
46.4%
346/745 • Number of events 673 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Asthenia
|
10.1%
8/79 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
33.3%
53/159 • Number of events 126 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
37.9%
158/417 • Number of events 365 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
34.1%
254/745 • Number of events 671 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Pyrexia
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.9%
11/159 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.6%
40/417 • Number of events 51 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.0%
119/745 • Number of events 152 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Oedema peripheral
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.9%
11/159 • Number of events 17 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.6%
40/417 • Number of events 48 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.2%
76/745 • Number of events 95 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Mucosal inflammation
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.9%
11/159 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.9%
37/417 • Number of events 47 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.4%
70/745 • Number of events 104 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
General disorders
Pain
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.7%
28/417 • Number of events 33 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.8%
51/745 • Number of events 67 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Anaemia
|
13.9%
11/79 • Number of events 18 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
44.0%
70/159 • Number of events 167 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
64.5%
269/417 • Number of events 914 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
65.1%
485/745 • Number of events 1755 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Neutropenia
|
6.3%
5/79 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
31.4%
50/159 • Number of events 115 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
37.4%
156/417 • Number of events 442 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
34.9%
260/745 • Number of events 764 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
3.8%
3/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.8%
22/159 • Number of events 40 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
39.3%
164/417 • Number of events 477 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
35.3%
263/745 • Number of events 796 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Blood and lymphatic system disorders
Leukopenia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
8/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.0%
29/417 • Number of events 98 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.5%
63/745 • Number of events 157 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Neuropathy peripheral
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
47.8%
76/159 • Number of events 128 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
41.5%
173/417 • Number of events 322 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
41.9%
312/745 • Number of events 551 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Headache
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
26.4%
42/159 • Number of events 57 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
25.4%
106/417 • Number of events 182 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
26.7%
199/745 • Number of events 307 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Dizziness
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.1%
16/159 • Number of events 21 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.1%
63/417 • Number of events 93 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.8%
125/745 • Number of events 176 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Peripheral sensory neuropathy
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.7%
25/159 • Number of events 45 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
14.1%
59/417 • Number of events 95 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.8%
118/745 • Number of events 193 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Dysgeusia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.1%
16/159 • Number of events 18 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.2%
34/417 • Number of events 43 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.4%
85/745 • Number of events 104 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Paraesthesia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.6%
40/417 • Number of events 53 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.4%
55/745 • Number of events 74 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Nervous system disorders
Neurotoxicity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.1%
13/417 • Number of events 28 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.4%
25/745 • Number of events 46 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
5.1%
4/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
41.5%
66/159 • Number of events 79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
46.3%
193/417 • Number of events 258 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
44.0%
328/745 • Number of events 411 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Rash
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
12.6%
20/159 • Number of events 30 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.5%
48/417 • Number of events 62 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
21.2%
158/745 • Number of events 313 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.5%
12/159 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.6%
44/417 • Number of events 72 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
18.5%
138/745 • Number of events 200 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Dry skin
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.2%
30/417 • Number of events 33 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.1%
53/745 • Number of events 57 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Skin and subcutaneous tissue disorders
Rash maculo-papular
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.1%
17/417 • Number of events 18 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.7%
57/745 • Number of events 84 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Platelet count decreased
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.7%
25/159 • Number of events 57 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
27.3%
114/417 • Number of events 349 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
30.7%
229/745 • Number of events 695 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Neutrophil count decreased
|
3.8%
3/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
18.2%
29/159 • Number of events 56 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
19.7%
82/417 • Number of events 228 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
24.3%
181/745 • Number of events 499 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Alanine aminotransferase increased
|
3.8%
3/79 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.5%
12/159 • Number of events 23 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.0%
46/417 • Number of events 102 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.4%
122/745 • Number of events 257 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Weight decreased
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.2%
21/159 • Number of events 29 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.8%
49/417 • Number of events 68 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
14.8%
110/745 • Number of events 178 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Aspartate aminotransferase increased
|
2.5%
2/79 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 17 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.8%
49/417 • Number of events 87 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.7%
117/745 • Number of events 254 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
White blood cell count decreased
|
7.6%
6/79 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.5%
12/159 • Number of events 25 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.9%
37/417 • Number of events 69 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
12.6%
94/745 • Number of events 284 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood creatinine increased
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.1%
38/417 • Number of events 76 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.0%
97/745 • Number of events 216 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Amylase increased
|
1.3%
1/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.8%
20/417 • Number of events 33 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.1%
60/745 • Number of events 117 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood alkaline phosphatase increased
|
1.3%
1/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.9%
3/159 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.4%
10/417 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.9%
59/745 • Number of events 137 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Investigations
Blood thyroid stimulating hormone increased
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.6%
19/417 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.8%
36/745 • Number of events 48 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
40.3%
64/159 • Number of events 132 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
37.2%
155/417 • Number of events 291 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
39.3%
293/745 • Number of events 527 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
18.9%
30/159 • Number of events 39 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
21.1%
88/417 • Number of events 151 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
21.9%
163/745 • Number of events 252 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.4%
26/159 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
14.1%
59/417 • Number of events 81 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.5%
123/745 • Number of events 163 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.9%
19/159 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.3%
47/417 • Number of events 71 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.0%
82/745 • Number of events 96 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Bone pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.9%
33/417 • Number of events 44 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
47/745 • Number of events 64 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.0%
25/417 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.7%
50/745 • Number of events 69 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.2%
26/417 • Number of events 32 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.8%
43/745 • Number of events 52 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Musculoskeletal and connective tissue disorders
Neck pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.3%
22/417 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
28/745 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Decreased appetite
|
10.1%
8/79 • Number of events 8 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
19.5%
31/159 • Number of events 40 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
24.0%
100/417 • Number of events 140 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
31.3%
233/745 • Number of events 388 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypomagnesaemia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
18.9%
30/159 • Number of events 46 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
21.8%
91/417 • Number of events 180 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
23.1%
172/745 • Number of events 313 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
7.6%
6/79 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.1%
16/159 • Number of events 27 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.3%
47/417 • Number of events 73 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
14.6%
109/745 • Number of events 247 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
5.1%
4/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.8%
20/417 • Number of events 49 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.2%
61/745 • Number of events 144 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.7%
32/417 • Number of events 49 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.8%
51/745 • Number of events 95 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Dehydration
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 11 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.8%
24/417 • Number of events 26 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.4%
40/745 • Number of events 49 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
8.9%
7/79 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.4%
7/159 • Number of events 14 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.6%
11/417 • Number of events 16 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.2%
39/745 • Number of events 104 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.9%
12/417 • Number of events 21 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.6%
19/745 • Number of events 28 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
Urinary tract infection
|
5.1%
4/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
17.0%
27/159 • Number of events 54 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
19.9%
83/417 • Number of events 140 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
19.2%
143/745 • Number of events 234 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Infections and infestations
COVID-19
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.1%
5/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
12.0%
50/417 • Number of events 55 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
12.9%
96/745 • Number of events 108 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
3.8%
3/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
12.6%
20/159 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
20.9%
87/417 • Number of events 127 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
24.6%
183/745 • Number of events 275 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.2%
21/159 • Number of events 26 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.9%
58/417 • Number of events 64 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.2%
121/745 • Number of events 164 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Epistaxis
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
13.2%
21/159 • Number of events 26 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
14.4%
60/417 • Number of events 79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
16.1%
120/745 • Number of events 166 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.1%
5/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
4.8%
20/417 • Number of events 20 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.5%
41/745 • Number of events 45 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Hypertension
|
3.8%
3/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
25.8%
41/159 • Number of events 81 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
30.2%
126/417 • Number of events 262 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
31.7%
236/745 • Number of events 509 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Vascular disorders
Hot flush
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.7%
17/159 • Number of events 22 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.0%
46/417 • Number of events 59 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.3%
69/745 • Number of events 78 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Insomnia
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
15.7%
25/159 • Number of events 31 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
20.1%
84/417 • Number of events 106 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
19.2%
143/745 • Number of events 176 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Anxiety
|
2.5%
2/79 • Number of events 2 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
11.3%
18/159 • Number of events 21 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
10.8%
45/417 • Number of events 55 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.4%
70/745 • Number of events 83 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Psychiatric disorders
Depression
|
2.5%
2/79 • Number of events 3 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 26 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.4%
40/745 • Number of events 51 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Infusion related reaction
|
3.8%
3/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.4%
15/159 • Number of events 24 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
9.6%
40/417 • Number of events 48 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.6%
49/745 • Number of events 61 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Injury, poisoning and procedural complications
Procedural pain
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 26 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.6%
42/745 • Number of events 47 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Proteinuria
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.3%
10/159 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.6%
36/417 • Number of events 78 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
8.1%
60/745 • Number of events 106 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Renal and urinary disorders
Dysuria
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 9 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.6%
15/417 • Number of events 19 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.6%
27/745 • Number of events 34 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.5%
27/417 • Number of events 32 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
20.1%
150/745 • Number of events 189 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Endocrine disorders
Hyperthyroidism
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.1%
5/159 • Number of events 5 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.9%
12/417 • Number of events 15 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.6%
42/745 • Number of events 47 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Palpitations
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
6/159 • Number of events 7 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.2%
26/417 • Number of events 37 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
7.0%
52/745 • Number of events 62 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Tachycardia
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.5%
4/159 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.6%
15/417 • Number of events 20 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.8%
43/745 • Number of events 60 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Cardiac disorders
Atrial fibrillation
|
5.1%
4/79 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.00%
0/159 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
0.96%
4/417 • Number of events 4 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
1.2%
9/745 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Eye disorders
Vision blurred
|
1.3%
1/79 • Number of events 1 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.7%
9/159 • Number of events 10 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.9%
12/417 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.9%
44/745 • Number of events 47 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Drug hypersensitivity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
3.8%
6/159 • Number of events 6 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
5.0%
21/417 • Number of events 32 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.7%
20/745 • Number of events 25 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/79 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
6.9%
11/159 • Number of events 12 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.4%
10/417 • Number of events 13 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
2.4%
18/745 • Number of events 23 • All-cause mortality, non-serious adverse event (SAEs) and SAEs were collected up to approximately 316 weeks.
All-cause mortality, non-serious adverse events (AEs), and serious adverse events (SAEs) were collected for all enrolled participants, including those who received only standard of care and no study intervention (not treated arm) and those who received at least one dose of a study intervention (arms 1, 2, and 3).
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.
- Publication restrictions are in place
Restriction type: OTHER